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ABSTRACT
Background: Traumatic brain injury (TBI) still remains a difficult disorder to treat. TBI has been
associated to chronic neuroinflammation and a high risk for neurodegenerative disorders. Since
2001 between ten to twenty percent of all deployed military members have suffered a combatrelated TBI. Nearly twenty to thirty percent of those will experience chronic cognitive,
behavioral and somatic symptoms after suffering a TBI.
Methods: The objective of this review is to evaluate current literature examining vitamin D as a
neurosteroid with protective properties and its clinical relevance after traumatic brain injury.
Vitamin D is known to participate in neurobiological processes and genomic regulation in the
brain. Clinical and laboratory findings support that vitamin D modulates the immune responses
to trauma, diminishes oxidative and toxic damage, and inhibiting activation and progression of
the neuroinflammation. Inadequate levels of vitamin D have been identified as a common risk
factor for many neurological disorders and have been linked to poorer recovery.
Results: This review found compelling evidence to support that the pathology of TBI is closely
associated with neuroprotective mechanisms of vitamin D. Low vitamin D levels are common
among US active duty military and veterans. The findings strongly suggest that optimizing
vitamin D prior to injury could improve the recovery for military members after experiencing a
TBI. Vitamin D ameliorates brain damage by modulating neuroinflammation, improving cell
survival and down-regulating mechanisms involved in the progression of cell damage following
a TBI. However, further studies are needed to evaluate the effects of vitamin D optimization in
TBI outcomes.
Keywords: vitamin D, low vitamin D, neuroprotection, traumatic brain injury, TBI , calcitriol
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CHAPTER 1: INTRODUCTION
Traumatic brain injury is characterized as a complex and multidimensional neurological
disorder (Brain Trauma Foundation [BTF], 2007; Institute of Medicine [IOM], 2011a; Stein,
2015). The onset of tissue and cellular alterations of TBIs emerge over a short period of time, but
the consequences of the acute tissue damage has been known to predispose patients to other
chronic neurological disorders, and shortens their lifespan (Chauhan, 2014; Daneshvar,
Goldstein, Kiernan, Stein, & McKee, 2015; Gardner & Yaffe, 2015).
Neurological disorders are complex. Uncertainty about the ideal management is related to
unclear or poorly understood mechanisms and an assortment of environmental, genetic and
physiological risk factors that amplify the uniqueness of the clinical presentations and
progression. In addition to this complexity, the diversity of outcome measures further
complicates the clinical picture (Maas et al., 2012; Groves, McGrath & Burne, 2014; Veterans
Affairs and Department of Defense [VA/DoD], 2016). Interestingly, a newly identified common
risk factor shared by many of the disorders is inadequate vitamin D levels. After correcting for
confounding variants, researchers have found that the incidence and symptom severity of
neuropsychiatric and neurodegenerative disorders remains higher for subjects with low levels of
vitamin D (Groves, McGrath & Burne, 2014).
In the last two decades, mounting epidemiologic evidence suggests that inadequate levels
of vitamin D may be associated with an elevated risk for brain disorders such as schizophrenia
(Cui et el., 2014; Groves, McGrath & Burne, 2014; Wrzosek et al., 2013), depression (Groves,
McGrath & Burne, 2014), autism, Parkinson’s disease (Cui et el., 2014; Groves, McGrath &
Burne, 2014), Alzheimer’s disease (Daneshvar et al., 2015; Groves, McGrath & Burne, 2014),
1

epilepsy (Groves, McGrath & Burne, 2014; Wrzosek et al., 2013), and brain atrophy (Annweiler,
Annweiler, Montero-Odasso, Bartha & Beauchet, 2014; Wrzosek et al., 2013). The range of
issues related to vitamin D deficiency speaks to a basic cellular set of activities that affect the
entire system.
Animal experiments and in-vitro studies have shown and described some of the
underlying mechanisms that produce the neuroprotective activities of vitamin D on brain cells.
Vitamin D is capable of modulating inflammatory cytokines (Groves, McGrath & Burne, 2014;
Holick, 2007; Moromizato et al., 2013; Wrzosek et al., 2013), offers antioxidant benefits (Eyles,
Burne & McGrath, 2013; Wrzosek et al., 2013), intracellular calcium regulation (Annweiler et
al., 2014; Cui et el., 2014; Eyles, Burne & McGrath, 2013; Groves, McGrath & Burne, 2014;
Wrzosek et al., 2013), neurotrophic enhancement (Annweiler et al., 2014; Eyles, Burne &
McGrath, 2013; Groves, McGrath & Burne, 2014; Wrzosek et al., 2013), protection of the BBB
integrity (Moromizato et al., 2013; Won et al., 2015), and may reduce the toxic damage from
proteins exiting damaged cells (Atif et al., 2013; Huang, Ho, Lai, Chiu, & Wang, 2015; Kajta et
al., 2009).
This review will evaluate the literature to determine whether or not there is compelling
evidence to support that vitamin D exerts a neuroprotective action in the acute phase following a
traumatic brain injury (TBI). There is preliminary evidence that low vitamin D is prominent
among active duty military (Alazzeh et al., 2015; Andersen et al., 2010; Bailey, Manning &
Peiris, 2012; Hiserote et al., 2016; Wentz, Eldred, Henry, & Berry-Caban, 2014), a population
with high prevalence of combat injuries involving trauma to the head (Bryan, 2013; Chauhan,
2014; IOM, 2011a; McKee & Robinson, 2014; Twamley, Jak, Delis, Bondi, & Lohr, 2014;
2

Troyanskaya et al., 2015; Department of Veterans Affairs & Department of Defense [VA/DoD],
2016; Vakhtin et al., 2013). This paper develops an argument for further investigation regarding
the potential protective effect of vitamin D optimization on recovery from TBI, particularly for
military personnel.
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CHAPTER 2: METHODOLOGY
Due to the lack of studies evaluating the existence of a relationship between vitamin D
and TBI, this review focused on articles concerning the neuroprotective effect of vitamin D on
brain tissue. Publications were identified via Ebsco on the following databases: Medline, Cinahl
Plus, Academic Search Premier, Conchrane Controlled Trials and Conchrane Systematic
Reviews. Terms used for the initial search parameters included: inflammatory cytokines, or
neuroinflammat*, or neuron* disruption or blood-brain barrier or BBB or BBB leakage or
membrane leakage or L-type calcium channels or calcium channel or brain intracellular calcium
or reactive oxygen species or ROS or oxidative stress or neurodegene* or ion gradients or
excitotoxic* or cerebral edema or neuroedema or apoptosis or neurotrophic or lipid peroxidation
or hypoxi* or vitamin d receptor or VDR or antioxidant or neuroprotect* or regulat* or modulat*
or cytotoxic* or neuroprotective agent. Additionally, two different groups of terms were used to
narrow down the specificity of the results; one using multiple terms for vitamin D and the other
for TBI (full list of terms is available on Appendix A). Results were limited to publications in
English, between 2006 and 2016.
Titles and abstracts were screened for inclusion/exclusion criteria with 14 articles
selected. Duplicates across databases were removed during initial screening. The exclusion
criteria included: (1) studies related to science or medical specialties other than neurology; (2)
sample size of 1 patient; (3) age group: neonates, child* or infant or embryonic or pediatric or
adolesce* or 0-18 years or birth or pregnancy or aged or aging or elderly or over 65; (4) did not
include at least one of the topics from the inclusion criteria.
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The inclusion criteria encompassed the following: (1) vitamin D neuroprotective effects
in brain/axonal/neuronal injuries through mechanisms involving (2) neuroinflammation, bloodbrain barrier integrity, L-type calcium channel, oxidative stress/reactive oxygen species (ROS)
and excitotoxicity. Of the articles that met the inclusion criteria included 11 were primary
research articles/animal model experiments, 1 randomized control trials (RCT) and 2 literature
reviews.
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CHAPTER 3: TRAUMATIC BRAIN INJURY BACKGROUND
Traumatic Brain Injury (TBI) comes in many forms. The characterization and definition
of TBI is still yet to reach consensus (Gardner & Yaffe, 2015; Stein, 2015; VA/DoD, 2016). This
should not come as a surprise, considering that the multidimensionality of the disorder results in
a substantial assortment of clinical signs and symptoms severity, structural and functional
alterations and heterogeneity of outcomes (BTF, 2007; IOM, 2011a; Stein, 2015). The most
recent VA/DoD practice guidelines state that regardless of a confirmed exposure to an external
force, a positive TBI diagnosis requires the reporting of one or more of the TBI clinical criteria
immediately after sustaining an injury (VA/DoD, 2016).
Traumatic brain injuries occur after a person suffers an external blow to the head and the
severity can range from mild (concussion symptoms) to severe (coma) (World Health
Organization [WHO], 2006). The U.S. Centers for Disease Control and Prevention (CDC) and
the Department of Defense (DoD) defined TBI as:
a traumatically induced structural injury and/or physiological disruption of brain function
as a result of an external force and is indicated by new onset or worsening of at least one
of the following clinical signs immediately following the event: (1) any period of loss of
or a decreased level of consciousness; (2) any loss of memory for events immediately
before or after the injury (posttraumatic amnesia); (3) any alteration in mental state at the
time of the injury (e.g., confusion, disorientation, slowed thinking, alteration of
consciousness/mental state); (4) neurological deficits (e.g., weakness, loss of balance,
change in vision, praxis, paresis/plegia, sensory loss, aphasia) that may or may not be
transient; or, (5) intracranial lesion. (VA/DoD, 2016, p. 6)
6

Prevalence of Traumatic Brain Injury
The World Health Organization (2006) classifies TBI as one of the leading causes of
disease burden worldwide for individuals under 40 years of age. TBI has been associated with
almost fifty percent of all trauma related fatalities and are two to three times more common in
males than on females (WHO, 2006). If the forecasted twofold increase of TBI by 2020 is
fulfilled, it will become the third leading source of fatality and disability globally (FernándezGajardo et al., 2014).
Each year around 42 million individuals worldwide suffer a mild TBI (mTBI) (Gardner
& Yaffe, 2015). In the United States, the number of emergency visits linked to TBIs are
estimated between 1.7 and 2.2 million per year (Curtis & Epstein, 2014; VA/DoD, 2016; Vakhtin
et al., 2013), and about 30% of deaths resulting from trauma are connected to TBI (Vakhtin et
al., 2013). Every year approximately 52,000 deaths are caused by severe TBIs and 80,000
Americans (Sheriff & Hinson, 2015) join the estimated five million that live with a disability
after experiencing a TBI (Chauhan, 2014; WHO, 2006).
Among the civilian population, TBIs are most commonly caused by motor vehicle
accidents, falls, violence or sport-related injuries (Gardner & Yaffe, 2015; WHO, 2006). Reports
of TBI prevalence among the military vary, however there is consensus on improvised explosive
devices (IEDs) as the leading mechanism of injury for head trauma among active service
members of Operation Iraqi Freedom and Operation Enduring Freedom (IOM, 2011a; VA/DoD,
2016). Intracranial injuries from IEDs involve a series of mechanical forces (shear stress,
projectile debris, compression, pressure and tension) starting from the high energy center of the
7

explosion and many variables can impact the severity of the damage (VA/DoD, 2016).
Researchers are actively working in deciphering the exact mechanisms behind blast-related acute
structural changes (Goldstein, McKee, & Stanton, 2014).
Between 2001 and 2011, fatalities of the Iraq/Afghanistan conflicts combined
documented 42% of casualties that were related to motor-vehicle or air-craft crashes; between
11-18% were registered as penetrating head injuries from bullets or projectiles from explosive;
and about 15-20% were blast-related TBI. Thus, 26-38% of all deaths were directly linked to
brain trauma and the majority were blast-related. Moreover, during 2004-2008, penetrating TBIs
exceeded the number of closed or blast-related TBIs in a 2:1 ratio, a drastic decline in the
occurrence of penetrating brain trauma was noted during the following three years (2008-2010),
with a new 1.3:1 ratio (Chauhan, 2014).
According to a 2014 CDC report to Congress, between 2000 and 2011 the DoD
documented 235,046 active duty personnel had a TBI diagnosis among the approximately 5.5
million Army, Air Force, Navy and Marine Corps service members (VA/DoD, 2016). However,
prevalence estimates vary, even between different military sources. The CDC and other military
sources, estimate that between ten to twenty percent of all deployed military members
(Daneshvar et al., 2015) have suffered a blast-related TBI caused by IEDs (Bryan, 2013;
Chauhan, 2014; Daneshvar et al., 2015; Gardner & Yaffe, 2015; McKee & Robinson, 2014;
Twamley et al., 2014; Vakhtin et al., 2013; VA/DoD, 2016), and the majority are classified
within the range of mild to moderate severity (Daneshvar et al., 2015; Maas et al., 2012; McKee
& Robinson, 2014; Twamley et al., 2014; VA/DoD, 2016). According to Troyanskaya and
colleagues (2015), twenty-five percent of combat zone emergency evacuations report injuries to
8

the head and neck and about fifteen percent of those who served in Operation Iraqi Freedom
recounted having experienced a mTBI (Troyanskaya et al., 2015).
In 1992, Congress created the Defense and Veterans Brain Injury Center (DVBIC)
following the recommendations from the Department of Defense (DoD) and the Department of
Veterans Affairs (VA) on the relevance of TBI as a medical priority for the military. The purpose
behind the DVBIC was to have a multidisciplinary team serve as a hub for the advancement of
education and research, and the delivery of patient centered clinical care (IOM, 2011a).
Improving knowledge on functional impairments following TBIs, the influencing factors that
may contribute to persistency of symptoms and short- and long-term prognosis are at the top of
the priorities (VA/DoD, 2016).
A small recent retrospective study underlined that vitamin D levels lower than 16ng/mL
were prevalent in patients with a history of TBI, and showed a substantial negative association
with cognitive test results, regardless of the severity or time since the injury. Those same
25OHD3 levels were inversely proportionate to the scores of the depression inventory. Overall
levels were significantly lower than the general population, with 80.2% testing <26ng/mL, of
which 46.5% were at less than 16ng/mL. These suggest that lower levels are more prevalent
among post-TBI patients (Jamall et al., 2016).
Blast-related TBI.
The role of blast exposure as an etiology for brain trauma (Goldstein, McKee, & Stanton,
2014) was first reported among World War I infantry soldiers. The force from an explosion can
generate a wide diversity of injuries compounded together into one (Daneshvar et al., 2015). The
severity of a blast-related TBI is determined in part by the distance from the initial blast and
9

environmental differences such as exposure while out in the open versus inside of a vehicle and
whether or not the person had properly secured personal protective equipment. Even low
intensity recurrent blasts have been documented to cause neuronal tissue alterations (Goldstein,
McKee, & Stanton, 2014).
A distinct characteristic of blast injuries is the additive neuronal damage caused by
multiple forces (VA/DoD, 2016). The strong winds from the blast are traveling at such extreme,
sustained speeds that can generate a shockwave capable of producing multiple intervals of
dangerous, drastic contraction and expansion of tissue in fractions of a second. The shockwave
may cause diffused or focal bleeding and inflammation as the result of shearing and tearing of
neurovascular and neuronal tissues (Daneshvar et al., 2015). The violent atmospheric pressure
changes of the blast generate projectile debris elevating the risk of penetrating or blunt injury, or
both (Chauhan, 2014; VA/DoD, 2016). Lastly, as the body is tossed by the explosion, the brain
remains susceptible to harm from the displacement of tissue inside the skull from rapid
acceleration/deceleration and the risk of withstanding additional blunt to the head at landing
(VA/DoD, 2016). Blast-related TBIs present with a collection of heterogeneous lesions
representative of the many mechanisms of injury involved (Daneshvar et al., 2015).

TBI Pathophysiology
Brain tissue is organized into gray matter and white matter. Gray matter functions as the
central nervous system (CNS) data processor and it is primarily composed by cell bodies and
unmyelinated axons. White matter composition is predominantly myelinated axons,
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oligodendrocytes, and other types of glia cells. It is a crucial element of the brain communication
network, carrying transmission of signals between brain regions (Shi et al., 2015).
The brain’s proper functions are tied to the cellular and interstitial environments.
Cytoplasmic and interstitial parameters are maintained by interactions among neuroglia
(microglia, oligodendrocyte and astrocyte) cells, endothelial cells of the BBB and neurons.
Membrane proteins and signaling between cells enable adequate supply of oxygen and glucose
for energy production, support electrolyte transport from general circulation, and facilitate the
removal of metabolic waste (Chauhan, 2014; Shi et al., 2015).

Figure 1: Endothelial Cells of the BBB, Neuroglia and Neuron.
Adapted from “Demyelination as a rational therapeutic target for ischemic or traumatic brain injury”
by H. Shi, X. Hu, R. K. Leak, Y. Shi, C. An, J. Suenaga, J. Chen, & Y. Gao, 2015,
Experimental Neurology, 272, p. 20.

11

The pathogenesis of TBI begins when an external force disrupts structures and neuronal
homeostasis. Most TBIs present neurological deficits without or with minimally detectable
anatomical changes, regardless of the severity. The tissue disruptions arising immediately after
and as a direct consequence of biomechanical forces may include ischemia, neurovascular
integrity alterations, and microscopic axonal shearing, and are commonly referred to as the
primary injury or insult (Chauhan, 2014; Mayer, Huber & Peskind, 2013; VA/DoD, 2016; WHO,
2006).

Figure 2: Primary injury from TBI.
(Chauhan, 2014; Daneshvar et al., 2015; Fernández-Gajardo et al., 2014;
Mayer, Huber & Peskind, 2013; VA/DoD, 2016)

Co-occurrence of localized and widespread injuries from the same incident is quite
typical (Chauhan, 2014). Energy transfer from rapid acceleration and deceleration to the skull
causes brain tissue to shift, compromising cellular membrane and axonal cytoskeleton integrity.
Mechanical forces cause microscopic neurovascular disruptions that have been linked to the
clinical symptoms of TBI (Daneshvar et al., 2015; McKee & Robinson, 2014). Oftentimes,
cellular damage occurs on the primary side of impact and to the opposite side as the brain and
12

skull come to sudden deceleration and the brain hits against surrounding intracranial structures,
and it may rebound once more causing a secondary hit to the primary site of impact (VA/DoD,
2016).
Whether the damage is localized or widespread, the primary injury involves damage at
the cellular level to neurons, neuroglial and neurovascular tissues (Chauhan, 2014; FernándezGajardo et al., 2014; VA/DoD, 2016), and subsequently initiates various neuropathological
responses to the mechanical trauma that are classified as secondary injury or insult (Huang et al.,
2015). The secondary multifaceted response includes a series of interrelated and complex
molecular and cellular reactions involving macrophages, neuroglial cells, inflammatory
messengers, systemic immune activation, excitotoxicity, disruptions of the blood-brain barrier,
electrophysiological and ionic disturbances, and neurometabolic interruptions (Chauhan, 2014;
Mayer, Huber & Peskind, 2013).
Common concerns during the secondary injury phase include neuroinflammatory
activities, disruptions of the signal transmission, influx of calcium into cells, metabolic demands
and abnormal electrophysiology, toxicity from blood-brain barrier leakage and buildup of
neurotransmitters, intracranial edema and oxidative stress (Chauhan, 2014; Fernández-Gajardo et
al., 2014; Mayer, Huber & Peskind, 2013; VA/DoD, 2016). Increased energy demands following
trauma increases intracellular glucose requirements and releases catecholamines to stimulate
glucose transport which in turn elevate serum glucose concentrations, producing acute
hyperglycemia. After a TBI, high glucose attracts neutrophils to the wounded region intensifying
the intracellular alterations, such as acidosis and production of reactive species, worsening of the
extracellular detrimental environmental conditions including elevation of glutamate. Lastly, it
13

aggravates the inflammation by promoting glia secretion of pro-inflammatory mediators
(Chauhan, 2014).

Figure 3: Acute hyperglycemia during TBI secondary injury cascade (Chauhan, 2014).
Adapted from “Traumatic brain injury,” in Neurowiki, 2013, retrieved June 30, 2016,
from http://neurowiki2013.wikidot.com/individual:traumatic-brain-injury.
Copyright 2009 by E. Park, J. D. Bell, I. P. Siddiq & A. J. Baker.

The sums of the cytotoxic and neuroinflammatory processes collectively provoke cellular
edema, oxidative stress, destruction of the mitochondria and eventually activate neuronal
apoptosis (Chauhan, 2014). To appreciate the full profile of anatomical responses to the primary
injury it is important to understand that multiple types of cells are involved in dynamics taking
place simultaneously inside and outside of the affected cells. The responses are part of built-in
mechanisms involving up- and down-regulations depending on the stimuli. The activation and
14

progression of inflammatory processes, even with the original purpose of tissue protection may
exacerbate damage from trauma (Chauhan, 2014; Mayer, Huber & Peskind, 2013), and explains
the neurological symptoms that develop following a TBI (Fernández-Gajardo et al., 2014). Even
to this day, the multifaceted biological and structural alterations that occur as a result of a TBI
are not fully understood (IOM, 2011a; Mayer, Huber & Peskind, 2013; VA/DoD, 2016). The
following basic biologic mechanisms/steps are focused on processes where vitamin D is
involved. Appendix B, contains a table of inflammatory mediators categorized by pro- and antiinflammation with a brief description of their actions.
Neuroinflammation, excitotoxicity and oxidative stress.
Normally, the immune system inflammatory responses are aim at promotion of
restorative and reparative actions (Fernández-Gajardo et al., 2014). In the central nervous system
(CNS), inflammatory responses are controlled by CNS-devoted immune cells found in the
interstitial space and are commonly referred to as neuroglia or glia. Activation of glia cells is
generally inhibited by healthy neurons. Primary and secondary injuries stimulate concurrent
release of proinflammatory mediators and elicit glia activation and proliferation (Mayer, Huber
& Peskind, 2013).
Under typical conditions, the neuroglia or glia cells, comprised mostly of microglia and
astrocytes, are immune cells dedicated to survey for pathogenic threats or injury (Mayer, Huber
& Peskind, 2013). Clusters of activated microglia cells congregate at the site of injury
immediately after trauma (Chauhan, 2014). Neurotoxic molecules released by the glia following
activation from TBI are harmful to healthy cells, include reactive oxygen species (ROS), nitric
oxide (NO), proinflammatory cytokines and chemokines (Huang et al., 2015; Mayer, Huber &
15

Peskind, 2013). Normally, the cell’s built-in antioxidant system is able to keep ROS and NO
from harmful high concentrations. However, under extraordinary circumstances, when cellular
functions have been compromised, protective mechanisms struggle to safeguard the cell (Huang
et al., 2015).
Neuroinflammation causes neuroglial to become hyperactive, which in turn instigate the
phosphorylation of mitogen-activated protein kinase (MAPK) pathways. The ultimate goal of
these pathways is to generate nuclear transcription factors (NTF) to regulate cellular
inflammation, stress response, cell growth, differentiation and apoptosis (Hur et al., 2014).
Initiation of the extracellular signal-regulated kinase (ERK), p38-MAPK and Jun-N-terminal
(JNK) MAPK pathways elicited by activated microglia after brain trauma is responsible for the
signaling actions to stimulate synthesis of proinflammatory mediators capable of furthering brain
damage (Fu et al., 2013; Huang et al., 2015). Thus, the disproportionate or extended activation of
microglia following traumatic injury may exacerbate neuronal damage by maintaining a cycle of
glia activation and neuronal injury progression (Huang et al., 2015).
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Table 1: Mitogen-activated protein kinase (MAPK) pathways
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cell membrane & nuclear membrane

Astrocytes are advantageously located between the neurovascular and neuronal cells with
the purpose of regulating essential interactions concerning the BBB. Neurons rely on them for
almost all of their cellular functions, counting on astrocytes to regulate concentrations of
neurotransmitters, mediate synapsis and preserve ionic balances. It should not be a surprise that
they outnumber any other type of cell in the brain. After head trauma, their activation can be
triggered by damaged neurons or microglia activation. Activated astrocytes are beneficial in
isolating injured neurons by substrate deposition after a traumatic event. However, this barrier
also impedes axonal communication and restoration. They are also vulnerable to structural
damage themselves, not only unable to support neuronal homeostasis, but releasing
inflammatory mediators as well (Mayer, Huber & Peskind, 2013).
Oligodendrocytes’ responsibilities include making, maintaining and regenerating the
myelin sheath supporting the neuronal axons actions and integrity. However, they are
particularly vulnerable due to a low capacity to fight the oxidative stress that follows head
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trauma. The unmet demand of energy following acute trauma can reduce the cell’s ability to
perform its functions and lead to permanent loss of the myelin. Demyelination contributes to
neuronal transmission alterations and cause neurological symptoms after TBI. Therapeutic
approaches targeting oxidation and mitochondrial dysfunction could prevent or ameliorate
axonal demyelination (Shi et al., 2015).
As neuroinflammation continues, Schwann cells become activated as well and contribute
to the transmission dysfunctions of the wounded axons (Mayer, Huber & Peskind, 2013).
Intracellular edema along with ionic and metabolic changes, eventually lead to further structural
damage of the axons and infiltration of macrophages (Chauhan, 2014).
Excessive or persistent inflammatory response has been considered as a possible
explanation for neurological deficits following a TBI (Mayer, Huber & Peskind, 2013). Multiple
autopsy studies of individuals with mTBI found abnormal tissue structures correlated with
neuroinflammation. Findings supporting inflammation included signs of axonal injury such as
demyelination, varicosities, axonal bulbs at site of detachment and Wallerian degeneration, and
clusters of activated microglia and macrophages containing degenerated myelin have also been
found in the same area. All these alterations can be expected closely after trauma, except that
these findings were observed up to 18 years post-TBI, in additions to thinning of neuronal tracts
(Mayer, Huber & Peskind, 2013). Finding ways to mitigate, prevent or stop the overactive glia
has been identified as a potential treatment target for TBI (Huang et al., 2015).
Neuroinflammation is intimately related to oxidative stress and excitotoxicity as
originators and promoters of cellular damage. Their combined actions can consequently elicit
cell necrosis, apoptosis and autophagy. Oxidation damage can initiate multiple pathways to
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regulate cell death. Mitochondrial lysis is another known way to trigger apoptosis. Signs of
apoptosis in autopsies of TBI patients have been observed up to a year after the original
mechanical trauma. Autophagy initiated during ischemia/reperfusion, hypoxic stress or post-TBI
is mostly driven by oxidative stress. Laboratory and clinical findings have identified a genetic
pathway promoting autophagy after TBI (Fernández-Gajardo et al., 2014).
Oxidative stress from reactive oxygen and nitrogen species is known to occur in the brain
after TBI and the antioxidant actions directly rely on the BBB to attain the best possible effects.
Damage is subsequent to the discrepancies between high concentrations of reactive species and
the cell’s overwhelmed antioxidant mechanisms. Because of low antioxidant capacity, high
demand for oxygen and high amounts of iron, neurons are particularly susceptible to elevation of
reactive oxygen species (ROS) and reactive nitrogen species (NOS) following brain trauma
(Fernández-Gajardo et al., 2014).
ROS contributions to intracellular damage are excitotoxicity, calcium influx, intracellular
edema and metabolic collapse. ROS also facilitates structural weakening and disruption of the
neurovascular vessel walls, thus increasing the permeability of the blood-brain barrier (BBB).
Cell damage from oxidation causes declines in brain-derived neurotropic factors consequently
worsening cognitive decline and neuronal communication (Fernández-Gajardo et al., 2014).
At the beginning of the secondary injury phase, a sudden neuronal membrane
depolarization precedes the colossal release of the neurotransmitter glutamate. Glutamate efflux
surpasses the reuptake ability of astrocytes (Charier et al., 2015). Excitotoxicity from glutamate
triggers harmful influx of calcium ions, which precedes a series of neurotoxic events within the
cell, augmenting cell edema and production of NOS. Glutamate toxicity harms the affected cells
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as well as neighboring cells and creates a risk for apoptosis on all glutamate-stressed cells
(Fernández-Gajardo et al., 2014).
Temporary increases of amyloid β and its precursor protein in the axons takes place
following a TBI (Daneshvar et al., 2014). Studies showed that multiplied levels of amyloid β
promote low-voltage calcium channel expression and suppressed the vitamin D receptor (GezenAk, Dursun & Yilmazer, 2013).

Figure 4: Inflammatory mediator, oxidative stress and excitotoxicity.
Adapted from “Traumatic brain injury,” in Neurowiki, 2013, retrieved June 30, 2016, from
http://neurowiki2013.wikidot.com/individual:traumatic-brain-injury. Copyright 2009 by E. Park, J. D. Bell,
I. P. Siddiq & A. J. Baker.
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Diffuse axonal injury.
Neurovascular vessels and axons are particularly susceptible to damage from rapid brain
shifting because of their elongated structures (Daneshvar et al., 2015; McKee & Robinson,
2014). Diffuse axonal injury (DAI) or traumatic axonal injury (TAI) is seen in all types of TBIs,
thus it is considered the signature injury of TBI (Daneshvar et al., 2015).
DAI is a dynamic process characterized by widespread microscopic injuries, that unfolds
over time as a result of mechanical interruptions and membrane perforation to white matter tracts
or axons. Compromised membrane integrity allows drastic influx of calcium while driving
potassium out of the cell (Chauhan, 2014; Daneshvar et al., 2015; McKee & Robinson, 2014).
Calcium influx stimulates sodium-calcium (Na+/Ca++) pumps and sets in motion regulatory
actions of calcium-dependent enzymes to catabolized damaged proteins. The sudden increase of
intracellular calcium leads to mitochondrial membrane leakage and axonal energy production
collapses (Chauhan, 2014). Mitochondrial energy breakdown is a known predictor for poor
outcomes (Fernández-Gajardo et al., 2014). Meanwhile, the Na+/Ca++ pumps continue to
exacerbate the burden on the axon cytoskeletal structures and the mitochondria by importing
more calcium ions into the cell. Finally, the process of axonal degeneration culminates with
necrosis and apoptosis (Chauhan, 2014).
Cellular changes that arise from the stretching and tearing of axons begin minutes to
hours following the primary insult. Ramifications of the intracellular calcium overload include
damage to the transmission structure on the cell and impaired transport. The large amount of ion
transport proteins along the nodes of Ranvier makes this area particularly susceptible to
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deterioration from calcium influx and membrane disturbances (Chauhan, 2014; Daneshvar et al.,
2015).
Continuation of calcium import, with impaired ionic and neurotransmitters transport and
intermittent areas of inflammation along the axon stimulate the formation of axonal varicosities
and lead to further structural degeneration and deformations. Axonal varicosities are
concentrated areas of inflammation considered weakened structural points along axonal
cytoskeleton. Within minutes to hours after trauma, localized swelling and the buildup of untransported molecules lead to severed axons from the body of the neuron and creates axonal
bulbs at the detached ends of the axon, at the breaking point, usually at the level of the nodes of
Ranvier (Chauhan, 2014).
As the axonal ends separate from the cell bodies, communication between different
regions of the brain cease and Wallerian degeneration is initiated. Wallerian degeneration is a
process in which the distal portion of a nerve fiber that has either been detached or damaged
begins to degenerate. Using a DAI experiment model, detection of DAI occurred fifteen minutes
after the injury. Axonal detachment was prevalent at thirty minutes and was followed by
Wallerian degeneration beginning two to three hours after trauma (Chauhan, 2014).
Compromised myelin sheath renders transmission of action potential down the axon
inoperable, impairs the cells energy sources and makes the unprotected axon more vulnerable to
degradation (Shi et al., 2015). Acute deterioration of the myelin sheath exposes the axon
facilitating infiltration of macrophages and Schwann cells. The progression of axonal
demyelination is believed to continue years after the original trauma and may be the source for
persistent symptoms and the effects of neuronal degeneration later in life (Chauhan, 2014).
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Blood-brain barrier disruption.
The BBB can be described as an adaptable interface that is capable of restricting access
to damaging substances from the circulatory system, while allowing crossing of necessary
nutrients and substances to sustain the ideal conditions for proper neuronal function. Normally,
neurovascular modifications that mediate these interactions occur from the influence of
astrocytes on endothelial cells (Mayer, Huber & Peskind, 2013).
Regulation of the endothelial tight junctions is an extremely important protective
mechanism for the brain since components of blood, plasma and peripheral leukocytes are toxic
to brain cells. Structural alterations to microvascularity from mechanical forces, damage to
astrocytes (Daneshvar et al., 2015; Mayer, Huber & Peskind, 2013), hypoxic death of endothelial
cells, or oxidative damage to tight junction protein structures (Won et al., 2015) may lead to
increased BBB permeability. Despite of the etiology, all TBIs whether from open or closed
trauma, will compromise brain microvascular cells of the BBB. Consequently, the neurotoxicity
caused by blood exposure exerting a pro-inflammatory action will increase activated glia and
leakage of BBB (Chauhan, 2014; Mayer, Huber & Peskind, 2013).
Infiltration of peripheral leukocytes join in with other brain immune defenses, and
lamentably, promote oxidative stress by increased production of nitric oxide (NO). The NO
interactions on the microglia membranes foster additional ROS synthesis and suppress enzymatic
activity necessary for the production of adenosine triphosphate (ATP) (Fernández-Gajardo et al.,
2014).
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Figure 5: Secondary injury from BBB breakdown.
Adapted from “Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body
Inflammation in Bipolar Disorder?,” Scientific figure on ResearchGate, n.d., Retrieved June 30, 2016, from:
https://www.researchgate.net/277352521_fig1_Proposed-model-of-blood-brain-barrier-BBB-disruption-inbipolar-disorder-Increased-BBB.

Large amounts of uncoagulated blood coming into contact with brain cells, as seen with
hematomas can cause severe brain edema and increased ICP. Edema and inflammation
compromised brain functions even further and require immediate medical interventions to
protect the brain cells (Chauhan, 2014). The infiltration of systemic leukocytes into the brain
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interstitial space prompts additional recruitment of glia and peripheral immune cells resulting in
a systemic immune reaction (Mayer, Huber & Peskind, 2013).
In summary, the pathological cascade triggered by different degrees of axonal and
neurovascular structural alterations is not tied to a single, isolated timed-event. Evidence
demonstrates that TBI damage is progressive in nature, with interlayering and complex
anatomical responses and may persist over a span of months, years or even decades.
Understanding the mechanisms triggering the secondary responses is crucial in order to develop
therapies to prevent or attenuate their impact.

Overview of TBI Clinical Management
Clinical management of TBI can be cumbersome, in part because of the progressive
nature of the disorder and complexities surrounding the wide variety of clinical signs. According
to the IOM (2011a), approaches aiming at one specific aspect of the pathological alteration postTBI have not yet succeeded and standardization of a particular consistent or effective protocol
for TBI management has not been achieved (IOM, 2011a).
The use of imaging studies and laboratory results for conclusive diagnosis, guidance of
clinical care or as prognosis predictors is not recommended (VA/DoD, 2016; WHO, 2006).
Timely recognition of TBI symptoms enables early clinical management, improves outcomes
and prevents undesirable consequences (WHO, 2006). It is important to underline that there is no
definite correlation between the documented degree of severity of TBI and patient prognosis
(Maas et al., 2012; Stein, 2015).
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The unpredictability of physiological responses seen with TBI is related to the distinctive
characteristics of the person at the time of the incident, amount and direction of the forces, and
environmental factors. Other factors likely to modify the body’s response may involve genetic
makeup, a prior diagnosis of TBI, overall health, nutritional and hydration status preceding the
incident, lack of sleep and high concentrations of stress hormones (VA/DoD, 2016).

Symptomology and Manifestations of Mild TBI
Given that the majority of reported TBIs are considered mild in severity (Gardner &
Yaffe, 2015; Maas et al., 2012; Mayer, Huber & Peskind, 2013; McKee & Robinson, 2014;
Stein, 2015; Twamley et al., 2014; VA/DoD, 2016), this section will focus on this data. It has
been proposed that microscopic structural lesions correspond to milder post-injury symptoms
(Daneshvar et al., 2015). However, the prevalence and severity of some symptoms have been
found to be higher in mTBIs than in more severe cases, as it is the case with post-traumatic
headaches (Mayer, Huber & Peskind, 2013). This seems to contradict the notion that the severity
of structural damage usually corresponds to the severity of the TBI.
Although the magnitude of structural damage may be narrower for an mTBI, the
metabolic and neuronal disruptions are thought to result from the aftermath of metabolic, ionic
and physiologic alterations rather than the structural changes. The pathological profile created by
the timing and magnitude of these anatomical responses has been known to progress into chronic
neurodegeneration in a subgroup of the population (VA/DoD, 2016).
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Figure 6: DoD TBI Diagnoses from 2002-2009.
Reprinted from “Clinical practice guideline for the management of concussion-mild traumatic
brain injury (version 2.0),” by VA/DoD, 2016, p. 101, Retrieved June 19, 2016, from
www.healthquality.va.gov/guidelines/Rehab/mtbi/.

Mild TBIs are characterized by lack of obvious anatomical trauma, the acute neurological
deficits tend to be categorized as mild and frequently resolve on their own in a matter of few
days or weeks (McKee & Robinson, 2014; WHO, 2006). However, about 10-15% of people will
be diagnosed with postconcussive syndrome, a condition characterized by persistency of TBIassociated symptoms (McKee & Robinson, 2014). The invisible manifestations of a single or
multiple close-head TBIs are often insidious and may take years to appear, though they may be
traced back to the initial injury (Daneshvar et al., 2015; IOM, 2011a).
During the initial assessment of mTBI patients may present with a combination of
physiological, cognitive and neuropsychological symptoms. Figure 7 contains the list of
symptoms highlighted in the VA/DoD mTBI practice guidelines that may indicate the need for a
neurological consult (VA/DoD, 2016).
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Figure 7: Initial presentation: Indicators for immediate referral.
Reprinted from “Clinical practice guideline for the management of concussion-mild traumatic
brain injury (version 2.0),” by VA/DoD, 2016, p. 17, Retrieved June 19, 2016, from
www.healthquality.va.gov/guidelines/Rehab/mtbi/.

Some commonly reported physiological symptoms are headaches, dizziness, nausea,
fatigue, sleep disturbances, and seizures (Chauhan, 2014). Roughly 30-90% of patients complain
of post-traumatic headaches (VA/DoD, 2016) and around 24-74% of dizziness, both symptoms
resolving within three months following an mTBI. Fatigue has been reported in about 73% of
TBI patients and has been linked to lower levels of social interaction and isolation. Sleep
disorders develop in about 30-73% of individuals diagnosed with TBI. Many of these symptoms
exist side by side and may contribute to neuropsychological or cognitive deficits. Researchers
found that improving sleep problems that developed after a TBI reduce the incidence of
psychological impairments (Chauhan, 2014).
At least one psychosomatic behavioral alteration has been reported for nearly all TBI
patients, involving the onset of depression, anxiety, or mood changes. Reports of post-TBI
cognitive symptoms include difficulties with concentration, attention, decreased processing
speed, impaired memory, judgement and problems with planning and multitasking (VA/DoD,
2016).
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Figure 8: List of possible mTBI symptoms from the VA/DoD algorithm for the management of mTBI.
Reprinted from “Clinical practice guideline for the management of concussion-mild traumatic
brain injury (version 2.0),” by VA/DoD, 2016, p. 17, Retrieved June 19, 2016, from
www.healthquality.va.gov/guidelines/Rehab/mtbi/.

Many of the symptoms reported by combat veterans recovering from TBI include
cognitive dysfunctions such as problems with concentration, memory impairment and executive
function irregularities (Daneshvar et al., 2015; Twamley et al., 2014). These deficiencies in
executive functions diminish a person’s ability to plan and organize their day, to manage their
time, or even completely quench their inability to multitask. Studies have indicated that cognitive
functionality can directly influence employability (Twamley et al., 2014). Thus, this shows that
special attention should be paid at resources available to ensure combat veterans can return to
their family and community with the highest level of reintegration and adaptability possible.

TBI Outcomes
TBI survival rates among combat-related wounded soldiers have increased significantly,
in part due to modern advances in personal protective armour (Vakhtin et al., 2013) and
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improved military medical interventions (Johannigman et al., 2015). Consequently, many
veterans are coming back home or being returned to active duty after surviving their injuries.
Holistic, patient-oriented TBI management aims at improving symptoms, quality of life
and functionality levels (VA/DoD, 2016). Most combat-related TBIs are considered mild in
nature (Daneshvar et al., 2015; Maas et al., 2012; McKee & Robinson, 2014; Twamley et al.,
2014; VA/DoD, 2016) and, although mortality rate is low, long-term disability is common
(Curtis & Epstein, 2014; WHO, 2006). Curtis and Epstein (2014) state that as many as 20% of
patients with a mild TBI will go on to experience chronic symptoms related to postconcussive
syndrome (Curtis & Epstein, 2014), other estimates are as high as 30% (Vakhtin et al., 2013).
Disability levels vary among veterans who have suffered one or more TBI and
rehabilitation outcome predictions are difficult. Severity of symptoms has been directly
associated with the degree of disability, poorer degree of functionality, lower reintegration in the
community and employability. Cognitive deficiencies contribute to learning difficulties that
decrease their ability to learn new skills or earn a new degree (Twamley et al., 2014).
An estimated 7% of Iraq and Afghanistan combat veterans receiving health care at VA
facilities continue to experience post-TBI symptoms related to cognitive deficits, sleep
difficulties, chronic fatigue, emotional problems and post-concussive headaches (Twamley et al.,
2014). However, it is unclear how the high frequency of neuropsychiatric comorbidities may
contribute to cognitive impairments (Troyanskaya et al., 2015; Twamley et al., 2014).
A small sample, not-blinded pilot study, found that twelve-weeks of cognitive
rehabilitation that included restorative and compensatory approaches could improve posttraumatic cognitive deficits and prospective memory in combat veterans with history of TBI,
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even with PTSD as comorbidity (Twamley et al., 2014). Other studies have found a direct
correlation between differences on the timing and quality of clinical care and rehabilitation
programs with the overall outcomes (Maas et al., 2012; Stein, 2015). It is sensible to conclude
that further examination of rehabilitation strategies may offer potential gains in service members’
rehabilitation outcomes.
Classification disparities among facilities and practitioners (Gardner & Yaffe, 2015) and
widespread treatment differences could explain some of the differences in outcomes (Maas et al.,
2012). Additional challenges concerning therapeutic effectiveness are embedded in an
unpredictable collection of physiological and environmental conditions. Genetic susceptibility,
preinjury psychosocial wellbeing as well as post-injury factors influencing psychosocial health,
pre-existing illness, the mechanism of trauma, as well as the quality and time of clinical care can
arbitrarily and collectively affect therapeutic outcomes. The need to expand understanding of the
multidimensionality of phenotypical expressions among comparable injuries is of utmost
significance (Maas et al., 2012; VA/DoD, 2016). Thus far, thirty-two transcription factors have
been related to genetic up-regulation following ischemic injury and are suspected to be involved
in inflammatory responses in rat brain cells (Ridder et al., 2009).
TBI is known to present with acute and chronic alterations of neuronal functions
(Daneshvar et al., 2015; Vakhtin et al., 2013). Multiple long-term complications that patients
with a history of TBI may face include reduction of life expectancy (Chauhan, 2014) and an
increased risk for developing neurodegenerative diseases later in life (Chauhan, 2014; Daneshvar
et al., 2015; Gardner & Yaffe, 2015).
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The body of evidence suggests that an isolated TBI may result in gray and white matter
degeneration and can trigger or speed up age-associated neuronal deterioration. It also increases
the likelihood of developing progressive neurodegenerative diseases such as Alzheimer’s and
Parkinson’s. Postmortem brain examinations of combat veterans with a positive history of blastrelated mTBI due to IEDs, showed evidence of tau neurofibrillary accumulation, chronic
traumatic encephalopathy (CTE), axonal and microvascular tissue damage, signs of proliferation
of astrocytes and microglial activation nearby lesions. The autopsies revealed initial signs of
CTE in four out of five of the deceased combat veterans that overlapped with a diagnosis of posttraumatic stress disorder (PTSD) in life, implying a possible connection between the pathology
of both conditions (Daneshvar et al., 2015).
A greater understanding of the immediate and lifelong consequences that mTBI has on
functioning still remains a priority for research. Moving forward, it is important for researchers
and clinicians to consider preventive, treatment and restorative strategies that can minimize the
disease burden among past, current and future military service members. Unemployment and
cognitive difficulties often co-exist. Reintegration programs for combat veterans dealing with
persistent neurological deficits of mTBIs and their families could provide resources and
cognitive training to support their transitions and improve their successful reintegration to the
community.
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CHAPTER 4: VITAMIN D BACKGROUND
Discovered in the early 20th century, vitamin D’s clinical relevance did not become
apparent until the connection of its extreme deficiency was identified as the leading cause of
rickets. First described in the mid-1600s, the clinical signs of rickets are visibly detectable as
bone deformities, growth delays and weakening of the muscles which were eventually seen as
being due to extreme hypovitaminosis D (Holick, 2006). Early experiments provided the data
needed to understand how rickets could be prevented by increasing sun exposure and vitamin D
dietary intake. In the early 20th century scientists were finally able to appreciate the
improvements on bone mineralization from this intervention, especially on the epiphyses of long
bones, by examining children’s x-rays (Holick, 2006; Eyles, Burne & McGrath, 2013).
The high prevalence of rickets, led the U.S. government to adopt the fortification of milk
with the fat-soluble nutrient as part of public health policy program for the prevention of rickets.
In 1928, the discovery of vitamin D’s chemical structure by Adolf Windausin (Eyles, Burne &
McGrath, 2013), facilitated new improvements for food fortification techniques (Holick, 2006).
The success of the policy became evident by the marked reduction of rickets cases in the mid1900s, almost eradicating the disease (Holick, 2006; Looker, Dawson-Hughes, Calvo, Gunter, &
Sahyoun, 2002; Rovner & O’Brien, 2008).

Vitamin D Photosynthesis
Photosynthesis.
Vitamin D is a fat soluble molecule that undergoes a complex process from initial
synthesis to activation before it can exert hormonal effects. Throughout a series of biochemical
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reactions, vitamin D exists in several different forms and goes by many different names
depending on the molecular structure. During the early stages of food fortification, the two
different forms of vitamin D were identified and classified as D2 or egocalciferol, which is found
in plants, and D3 or cholecalciferol, which is produced by animals. Fortification of food and oral
supplements use either form (Eyles, Burne, & McGrath, 2013; Holick, 2007; Holick et al., 2011).
In animals, the metabolic process of vitamin D3 begins when 7-dehydrocholesterol,
commonly known as “cholesterol,” an inert molecule on the epidermis layer of skin, is exposed
to the solar ultraviolet-B (UVB) radiation giving rise to cholecalciferol, the inactive form of
vitamin D3. The inactive molecule of vitamin D3 is transported in the circulatory system by
transport proteins to the liver where several P450 enzymes attach the first hydroxyl group in a
process known as hydroxylation. The newly formed 25-hydroxyvitamin D3 (25OHD3) or
calcidiol has a lifespan between two to three weeks, thus making it the ideal biological marker to
screen and monitor levels (Annweiler et al., 2014; Holick, 2007; Holick et al., 2011; Jamall et
al., 2016; Wang, Ji, Tong & Zhang, 2014; Wentz et al., 2014). 25OHD3 undergoes a second
hydroxylation in the kidneys from which the activated 1,25-dihydroxyvitamin D3 or 1,25OH2D3
emerges ready to function as a hormone (Eyles, Burne, & McGrath, 2013; Holick, 2006; Holick,
2007).
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Figure 9: Photosynthesis steps of vitamin D.
Adapted from “Vitamin D deficiency,” by M. F. Holick, 2007,
In The New England Journal of Medicine, 357(3), p. 269.

Vitamin D synthesized by sun exposure has been found to last twice as long in circulation
when compared to the orally ingested form. The skin is an extremely efficient source of vitamin
D. An estimated 1,000–1,500 hours out in the sun during the spring, summer and fall should
provide enough vitamin D for the majority of humans to cover for the winter months. One dose
of UVB irradiation, defined as the exposure needed by an adult dressed with a swimsuit to have
superficial pink tone 24 hours later, can generate the equivalent of 10,000-25,000 IU of oral
intake (Holick et al., 2011). Rovner & O’Brien (2008) stated that adequate synthesis of fair skin
individuals would require UVB radiation exposure for about 5 to 15 minutes between the hours
of 10 am and 3 pm during the abovementioned seasons. However, individuals with darker skin
may need five to ten times longer UVB exposure length for an equivalent production (Rovner &
O’Brien, 2008).
Factors influencing photosynthesis.
Vitamin D is a unique nutrient; although humans can ingest it from food sources,
including oral supplements, human skin is perfectly capable of synthesizing this nutrient to
adequate levels with appropriate exposure to sunlight. However, scientists have identified factors
that influence the body’s ability to produce vitamin D. Non-modifiable factors known to reduce a
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person’s ability to photosynthesize vitamin D include dark skin tone, age (decline of 7dehydrocholesterol), weather (cloud coverage and smog), cold seasons (shorter duration of sun
light) and latitude (higher than ~40°). On the other hand, adjustments to certain behaviors (length
of time spent outside, frequency and duration of exposure to UVB), type of clothing (degree of
skin coverage), dietary choices and supplementation that could potentially counteract the impact
of non-modifiable elements (Groves, McGrath & Burne, 2014; Harms, Burne, Eyles, &
McGrath, 2011; Holick, 2006; Holick, 2007; Looker et al., 2002; Rovner & O’Brien, 2008).
Individuals with dark skin tone require longer UVB exposure for adequate metabolism of
vitamin D3 due to higher concentration of melanin on their skin (Harms et al., 2011; Holick,
2007; Jamall et al., 2016). A decline in 7-dehydrocholesterol content in the skin is an expected
change observed with aging, thus the decrease of the molecular precursor for cholecalciferol
results in decreased synthesis (Holick, 2007). It has been reported that decreased intensity of
UVB radiation during the winter months accounts for the seasonal differences of vitamin D
photosynthesis, being especially significant in latitudes greater than ~40° (Holick, 2006; Holick,
2007; Looker et al., 2002). The photochemical smog of urban areas keeps sunlight from reaching
past it and might explain the higher occurrence of hypovitaminosis D when compared to rural
populations (Holick, 2007). Clothing and the application of sunscreen are known to decrease
skin exposure to UVB radiation thus reducing production of vitamin D (Eyles, Burne &
McGrath, 2013; Holick, 2006; Holick, 2007; Jamall et al., 2016).
Studies have found that certain medical conditions and medications increase the risk of
hypovitaminosis D. Sequestration of vitamin D in excess fatty tissue reduces the vitamin D
reaching circulation in obese individuals. In cases of liver and kidney insufficiency and failure,
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organ damage results in metabolic disruption of active vitamin D. Skin grafts or extensive burn
scarring deprive skin from its synthesis abilities (Holick, 2007). Medications for the treatment of
epilepsy and HIV/AIDS promote destruction of 25OHD3 and 1,25OH2D3 (Holick, 2007; Holick
et al., 2011).
Testing for hypovitaminosis D.
The Institute of Medicine (IOM) and The Endocrine Society (TES) concluded that the
evidence did not support regular screening of vitamin D levels except for individuals that are
considered to be at risk for deficiency (IOM, 2011b; Holick et al., 2011). It is important during
health assessments, to performed a thorough history intake that include questions on past medical
diagnosis, current medications, family history and certain behaviors, as the answers could guide
clinical judgement.
The Endocrine Society (2011) indicated screening when confirmed pathology of liver,
kidney or gastric systems is present and with metabolic and endocrine conditions known to alter
the metabolism of vitamin D (Holick et al., 2011). Clinicians should screen for deficiencies those
(1) with a body mass index above 30, (2) taking antiepileptic, antiretroviral, glucocorticoids, and
cholestyramine medications, (3) diagnosed with a malabsorption condition or (4) food allergies,
(5) renal or hepatic insufficiencies, (6) advanced age, or (7) primary hyperparathyroidism
(Holick, 2007; Holick et al., 2011). Screening is also important in persons with altered skin
functions, as seen with extensive scaring (Holick, 2007; Holick et al., 2011).
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Vitamin D Deficiency versus Insufficiency
At the time of this review, there is still no agreement concerning the assay criteria for
deficiency and insufficiency. According to Looker and colleagues (2002), deficiency occurs
when the levels of circulating 25OHD3 present with positive clinical symptoms of bone
demineralization, secondary hyperparathyroidism, or other signs of poor bone health.
Insufficiency, sometimes called subclinical deficiency occurs when levels are above deficiency
but low enough to contribute to bone disease (Looker et al., 2002) and other pathologies (Holick,
2007; Holick et al., 2011).
The medical community has struggled to reach the consensus necessary to identify
clinical guidelines for assessing, monitoring, and correcting vitamin D deficiencies (Eyles, Burne
& McGrath, 2013; Looker et al., 2002; Rovner & O’Brien, 2008; Wentz et al., 2014). The IOM
and TES do not concur on their clinical reference values or recommendations. In 2011, these two
major organizations published their own set of clinical guidelines for the screening, classification
and optimization practices (refer to table 2 for reference values) (Holick et al., 2011; IOM,
2011b).
Table 2: 2011 Vitamin D reference values from the IOM and TES.

Sufficiency
Insufficiency
Deficiency

IOM, 2011b
>20ng/mL (>50nmol/L)
<20ng/mL (<50nmol/L)

Holick et al., 2011
30 - 100 ng/mL (75 - 250nmol/L)
21 - 29 ng/mL (52 - 72nmol/L)
<20 ng/mL (<50nmol/L)

The significant relationship between vitamin D and the musculoskeletal system has been
established and accepted within the scientific community, and the mechanisms involved have
been extensively studied. The IOM indicated that their committee of experts appraised the newer
38

scientific evidence available since publishing their previous clinical practice guidelines in 1997
and did not find the data to be supportive of any health benefits beyond bone health. Thus, the
supplementation recommendation were designed to support optimal bone health based on the
minimum 25OHD3 levels necessary to support the musculoskeletal system. The institute’s 2011
update significantly increased the threshold for deficiency from 10ng/mL or 25nmol/L in 1997,
to 20ng/mL or 50nmol/L. It is important to underline in both occasions the guidelines were based
solely on bone homeostasis (IOM, 2011b).
The IOM set the adult vitamin D daily requirements to 400 IU (international units), with
a dietary allowance of 600 IU and a total upper limit of 4,000 IU. Referencing the data from the
NHANESIII survey, which showed daily dietary intake below standard requirements, the
committee deduced that adequate solar exposure may explain why average levels were higher
than 20ng/mL, which satisfies the cutoff proposed by the IOM. The committee raised concerns
about possible public misperceptions regarding vitamin D, driving a trend for increased
screenings and warns that inconsistencies on the cut-offs used between laboratories, which may
mislabel a person as deficient (IOM, 2011b).
In summary, the IOM’s dietary recommendations were established to keep a
concentration of at least 20ng/mL. The committee counsels against surpassing the daily upper
limit of 4,000 IU and warns that higher intake could come with detrimental risks to health and
that the likelihood of excessive intake is heightened by the availability of fortified foods and an
increased intake of supplements frequent in North America. The committee concludes that
additional research is needed in order to expand the health benefits of vitamin D (IOM, 2011b).
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In contrast with the IOM recommendations, after review of the available literature, The
Endocrine Society (TES) set forth guidelines which suggest vitamin D levels should be higher in
order to maintain health. The TES taskforce established the threshold for deficiency at 20ng/mL
or 50nmol/L, aligning with the IOM parameter. However, they also defined the range between
21-29 ng/mL as insufficiency, and determined the sufficiency range to be at of 30-100 ng/mL.
The insufficiency range was set just below the demonstrated ideal threshold in which parathyroid
hormone levels and adequate intestinal calcium absorption are believed to be optimally balanced.
When compared with the IOM report, the TES asserts that vitamin D deficiency is common in all
age groups and that few foods contain vitamin D, and recommends supplementation based on
age group and clinical presentation (Holick et al., 2011).
The TES taskforce indicated that optimization of vitamin D deficiency in adults can be
achieved by administering either D2 (egocalciferol) or D3 (cholecalciferol). They suggest that
healthy adults age 19 to 70 need at least 600 IU daily in order to maximize bone health and
muscle function, but clarified that 600 IU may not be enough to increase vitamin D levels above
30ng/mL consistently or to support other non-skeletal benefits. The daily requirement was set
between 1,500 and 2,000 IU for all adults in order to maintain 25OHD3 blood levels greater than
30ng/mL. In deficient adults older than 19 years of age initial supplementation involves 50,000
IU/week or 6,000 IU/day for two months to correct the deficiency, followed by the maintenance
dose of 1,500 to 2,000 IU a day (Holick et al., 2011).
The TES guidelines set a tolerable upper limit (UL) at 4000 IU/day for children between
1 and 8 years of age and 10,000 IU/day for anyone older than 9 years old, except for pregnant or
lactating teens, for which the 4,000 IU/day continues to apply. The committee decision to set the
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UL to 10,000 IU/day was based on a study in which men were supplemented with this dose for 5
months without reports of increase blood calcium concentrations or renal calcium excretion
(Holick et al., 2011).
Although the IOM committee warned that levels above 50ng/mL may be associated with
higher mortality, the TES did not support this claim and stated the evidence does not support any
disadvantages of increased intake, except for cases of lymphoma or chronic granuloma-forming
disorders (such as tuberculosis and sarcoidosis). The TES stated that an upper threshold to
prevent vitamin D toxicity has not been identified and the IOM UL recommendations were based
on observations from the 1940s. TES referenced studies in adults and children that showed
negative health concerns with 25OHD3 blood levels of 150ng/mL or above. For this reason they
believed an UL of 100ng/mL offers a safe parameter to prevent the risk of developing
hypercalcemia or hypercalciuria (increased calcium renal excretion) (Holick et al., 2011).
The TES does agree with the IOM in the desirability for better and more reliable assay to
measure vitamin D serum levels. Their report concludes and suggests that additional, highquality studies on vitamin D replacement and non-skeletal benefits are warranted in order to
solidify the evidence and develop stronger recommendations (Holick et al., 2011).

Prevalence of Low Vitamin D
Cases of extreme, chronic hypovitaminosis D (the type that leads to rickets) are rare in
the United States (Holick, 2006; Looker et al., 2002; Rovner & O’Brien, 2008). However, the
findings published by Looker and colleagues in 2002, confirmed significant vitamin D
deficiencies among noninstitutionalized adolescents and adults (Looker et al., 2002).
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Looker and colleagues analyzed the data collected as part of the Third National Health
and Nutrition Examination Survey (NHANES III 1988-1994), conducted by the U.S. National
Center for Health Statistics with the purpose of focusing on the status of 25OHD3 levels in the
population. The analysis accounted for differences in assessment methods by setting separate
cutoffs for radioimmunoassay (RAI) and competitive protein binding (CPB) test, since CBP
results tend to be 30% higher than RAI (Looker et al., 2002).
The cut-off point for vitamin D deficiency was set as a 25OHD3 blood level of <17.5
nmol/L (7 ng/mL) for the RAI, equating to <25 nmol/L (10ng/mL) when using the CPB, which
followed the IOM guidelines from 1997. Based on the cutoff used, less than 1% of the
participants tested were considered vitamin D deficient. Since there was no agreement for
insufficiency cutoff at the time of their analysis, the authors used four different ranges for the
calculations. The RAI values for insufficiency were set at (1) <25 nmol/L, (2) <37.5 nmol/L, (3)
<50 nmol/L, and (4) 62.5 nmol/L with corresponding CPB values between <37.5 nmol/L and
87.5 nmol/L (Looker et al., 2002).
The NHANES III sample included 18,875 participants, 12-years or older, that were
classified under three different ethnic/racial groups. Seasonal and latitudinal innate variances of
vitamin D synthesis were identified as confounding factors and corrected early on in the analysis.
In their analysis, the researchers concluded that regardless of seasonal and latitudinal differences,
insufficient levels of 25OHD3, defined as <37.5-62.5 nmol/L, were prevalent across all ages,
gender, race and ethnicity. The calculations found that for all surveyed participants of both
genders the percentage of occurrence for 25OHD3 of <37.5nmol/L (15ng/mL) was 2-19%; for
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the same sample the results showed 8-40% when using <50nmol/L (20ng/mL); and, when using
<62.5nmol/L (25ng/mL), the prevalence was 21-58%.
The results from the NHANES III led the Center for Disease Control and Prevention to
recognize that regardless of the food fortification efforts, varied degrees of subclinical
deficiencies are prevalent among all ages, genders, and latitudes of the country (Looker et al.,
2002). When using the 2011 recommendations for deficiency and insufficiency, up to 40% of the
population sampled would fall below <50nmol/L or <20ng/mL to be considered deficient (IOM,
2011b), and up to 58% would meet insufficiency criteria (Holick et al., 2011).

Physiology of Vitamin D
Once the epidemic of rickets was under control, the interest surrounding vitamin D died
down. Eventually it was discovered that biological interactions of vitamin D with body systems
extend far beyond musculoskeletal functions. In the 1970s and 1980s, new discoveries prompted
the reclassification of calcitriol (1,25OH2D3) as a hormone, launching a new area for scientific
research (Eyles, Burne & McGrath, 2013; Harms et al., 2011; Holick, 2006; Kesby, Eyles,
Burne, & McGrath, 2011; Rovner & O’Brien, 2008).
The abundance of the enzymes that activate and deactivate vitamin D and its receptors in
the brain suggest that vitamin D is a neurosteroid that regulates brain bioprocesses. The
expression of vitamin D receptors (VDRs) in the brain is capable of bioactivating 25OHD3 to
1,25OH2D3 (Groves, McGrath & Burne, 2014; Harms et al., 2011). Expression and activation of
the vitamin D receptors (VDR) during physiological activities can either exert genetic
transcriptional modifications or simply act as a membrane-associated rapid response steroid by
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influencing signaling mechanisms (MARRS) (Eyles, Burne & McGrath, 2013; Gezen-Ak,
Dursun & Yilmazer, 2013; Kajta et al., 2009; Ridder et al., 2009). The ability to follow genomic
or non-genomic paths is a commonality shared by other hormones categorized under the same
family (Eyles, Burne & McGrath, 2013). Post-mortem brain examinations of stroke patients
showed increased concentration of VDR in the region with infarction when compared to other
unaffected areas or subjects without a stroke (Ridder et al., 2009).
The actions of vitamin D on the biological processes related to bone health have been
studied extensively (Holick et al., 2011). When discussing dynamic biological processes, as with
bone turnover, it is important to note that multiple body systems, organs, cells types and
hormones collaborate simultaneously from different locations towards the completion of a
common biological objective. A concise version of just the demineralization portion follows as a
way to illustrate the parallel intricacies of biological processes.
The renal hydroxylation of 25OHD3 to produce 1,25OH2D3 or calcitriol, is tightly
controlled by the dynamics between serum concentrations of parathyroid hormone (PTH),
calcium and phosphorous. Generally, when the hypothalamic feedback mechanism signals low
calcium levels in the blood, it activates compensatory mechanisms which increase PTH secretion
from the parathyroid glands. PTH works by translocating calcium ions from storage by
dissolving bone tissue. In addition, when abnormal levels of serum calcium and phosphorous
concentrations are detected, 1,25OH2D3 interaction with VDRs in bone cells aid increase bone
dissolution and promote calcium reabsorption in the kidneys (Holick, 2006; Holick, 2007; Holick
et al., 2011).
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Meanwhile, expression of VDR in the small intestines improves dietary calcium
absorption from roughly 10-15% without 1,25OH2D3, to about 30-40% and dietary phosphorous
improves from 60% to 80%, in an attempt to balance their concentrations. Consequently, as
phosphorous concentrations rise in the bloodstream, bone tissue secretes molecules to signal the
kidneys to stop reabsorbing and start excreting excess phosphorous from the blood, and to reduce
absorption of phosphorous from dietary sources by decreasing renal activation of 25OHD3 to
1,25OH2D3. Thus, low vitamin D levels dampen the body’s ability to absorb dietary calcium and
phosphorous negatively impacting bone health and decreasing availability of these minerals
(Holick, 2006; Holick, 2007; Holick et al., 2011).
In children, prolonged renal excretion of phosphorus due to secondary
hyperparathyroidism causes bone deformities and it is known as rickets. Adults have fully
developed bones, thus the mineralization defects from the inadequate ratio of calcium and
phosphorus present as softening of the bones, a condition known as osteomalacia. Both
conditions share symptomatic similarities such as widespread bone and muscle pain, fatigue and
muscle weakness. Weakened muscles may contribute to difficulty standing, problems with gait,
recurrent falls and increase of stress fractures. In adults, the direct, long term consequence of the
bone demineralization is lower bone density, causing osteopenia and osteoporosis. Correction of
serum vitamin D levels, improve calcium balance and can prevent or correct secondary
hyperparathyroidism (Holick, 2006; Holick, 2007; Holick et al., 2011; Looker et al., 2002).
Since the recognition of vitamin D’s hormonal properties, converging evidence from
epidemiological, experimental and clinical studies has connected low vitamin D to negative
health outcomes distinct from skeletal outcomes (Braun et al., 2011; Cui et al., 2015; Daubail et
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al., 2013; McKinney et al., 2011; Moromizato et al., 2013; Turetsky et al., 2015; Wang et al.,
2014) and opened the possibility of supplementation as preventive intervention or treatment
(Amrein et al., 2014; Gominak & Stumpf, 2012). Retrospective and prospective observations
support that low levels of vitamin D yielded worse outcomes on cerebrovascular attacks (Daubail
et al., 2013; Turetsky et al., 2015; Wang et al., 2014), critically ill patients (Braun et al., 2011;
McKinney et al., 2011; Moromizato et al., 2013), lower cognitive scores, higher score for
depression inventory (Jamall et al., 2016), chronic fatigue in post-TBI (Schnieders, Willemsen,
& de Boer, 2012), and increased risk for many neuropsychiatric or neurodegenerative conditions
(Eyles, Burne & McGrath, 2013; Groves, McGrath & Burne, 2014; Harms et al., 2011; Holick,
2007; Kesby et al., 2011; Stein, 2015).
In a systematic review and meta-analysis concerning the association of vitamin D
deficiency and brain volumetric variations, Annweiler and colleagues (2014), concluded that
subjects with low vitamin D had lesser brain volume and larger ventricles when compared to
control subjects. Taking into account that vitamin D is a relatively new research interest, only a
few studies met inclusion criteria for the review, thus the connection of vitamin D to brain
atrophy remains to be confirmed (Annweiler et al., 2014). Similar volumetric findings from
animal studies have also been reported (Eyles, Burne & McGrath, 2013; Groves, McGrath &
Burne, 2014; Kesby et al., 2011).
Scientists from the University of Queensland, Australia, have done extensive work
exploring the neuronal implications of vitamin D in the brain, including distribution mapping of
VDR and the enzymes for activation/deactivation (1,25-hydroxylase and 24- hydroxylase) in the
human brain and the extraordinary similarities in the rat brains. Their collaborative work has
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created a large databank supporting the neuroprotective qualities of vitamin D (Eyles, Burne &
McGrath, 2013; Groves, McGrath & Burne, 2014; Harms et al., 2011; Kesby et al., 2011). Their
experiments in rats has provided compelling evidence implicating low vitamin D level during
gestational and early developmental age to structural alterations of the brain, genetic
modifications linked to neuronal potentiation, increased cell proliferation, decreased apoptosis
and cell differentiation, and deviations of dopamine (DA) signaling and breakdown (Eyles,
Burne & McGrath, 2013; Groves, McGrath & Burne, 2014; Kesby et al., 2011). Epidemiological
studies by the same group, demonstrated a significant risk for schizophrenia was inversely
related to 25OHD3 levels, with levels <16ng/mL displaying a twofold increased (Eyles, Burne &
McGrath, 2013).
Studies suggest an association between vitamin D and the incidence of neuropsychiatric
conditions including depressive disorders, schizophrenia, Alzheimer disease, Parkinson’s
disease, cognitive decline, dementia and autism, among others. For some of these findings
reverse-causation has not yet been discarded (Cui et al., 2015; Groves, McGrath & Burne, 2014;
Kesby et al., 2011). Groves, McGrath and Burne (2014) organized this information (see figure 10
below) to illustrate the type of studies and the findings categorized by disease (Groves, McGrath
& Burne, 2014).
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Figure 10: Strength of evidence based on animal studies, clinical trials, and epidemiological studies
that show evidence of an association between vitamin D and various disorders.
Numbers in boxes correspond to reference numbers (Groves, McGrath & Burne, 2014, p. 128).

Based on the evidence from prospective cohort studies, there is reason to believe that
vitamin D deficiency and insufficiency may contribute to cognitive decline in adults. Other
prospective studies have found similar evidence, in addition to linking marked vitamin D
deficiency to a significantly increase of the risk for Alzheimer disease and vascular dementia in
the 30 year follow up. However, failure to collect baseline cognitive data or to use objective tools
to test cognitive abilities limits the significance the findings (Toffanello et al., 2014).
Recent retrospective and observational studies found that prehospitalization low vitamin
D level is a solid predictor of mortality for ICU patients during hospitalization (Braun et al.,
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2011; McKinney et al., 2011; Moromizato et al., 2013), and at 30, 90 and 365 days from
admission mortality remained high for 25OHD3 levels <29ng/mL prior to hospitalization (Braun
et al., 2011). Another study revealed a strong connection between low 25OHD3 among critically
ill and an elevated likelihood of developing acute kidney injury (Moromizato et al., 2013).
A randomized double-blind trial of 492 ICU patients with 25OHD3 < 20ng/mL were
given either high doses of vitamin D or placebo for a period of five months. No statistical
significance was found in the length of hospitalization or time in the ICU. However, the
comparison of the fatality rates during hospital stay and at six months were lower for the group
receiving high-dose calcitriol supplementation (28.6% and 34.7% respectively) versus the
placebo group (46.1% and 50% respectively). After adjusting for covariate only the mortality
rate during hospital stay remained significant (Amrein et al., 2014). The results from this clinical
trial did not observe significant effect on the outcomes for patients with deficiency or
insufficiency prior to admission in the ICU, or even after levels were improved by aggressive
supplementation (Amrein et al., 2014). However, this peculiarity may be explained by results
from laboratory experiments and clinical trials that suggested levels prior to cell trauma or stress
offer the best neuroprotection, also the duration/timing of 25OHD3 exposure may have big
implications in responses (Kajta et al., 2009; Obradovic et al., 2009), and lastly, the effectiveness
of vitamin D may by directly related to a specific range of concentration (Atif et al., 2013;
Gominak & Stumpf, 2012; Hur et al., 2014; Kajta et al., 2009).
Low levels of 25OHD3 in patients suffering from headaches who were also diagnosed
with a sleep disorder and the discovery of high presence of VDR in regions of the hypothalamus
and brainstem known to regulate sleep, led researchers to hypothesize that vitamin D could
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possibly influence sleep patterns. A two year long, uncontrolled clinical trial of 1,500 patients
with complaints of headache, poor sleep and fatigue found a marked sleep quality improvement
following vitamin D supplementation regardless to the sleep disorder diagnosis. However,
decreased fatigue and sleep improvements were best achieved when 25OHD3 concentration
fluctuated between 60-80 ng/L (Gominak & Stumpf, 2012).
Studies have found that fatigue and sleep disorders are prevalent following a TBI
(Chauhan, 2014; Jamall et al., 2016; VA/DoD, 2016). A recent cohort study of TBI patients with
complaints of chronic fatigue, found that vitamin D levels <20ng/mL was the number one factor
shared by 65% of the cohort, when compared to poor sleep (54%), anxiety (36%), inadequate
levels of growth hormone (16%) and gonads hormonal deficiencies (9%). It is worth noting that
26.6% of the remaining was considered to have insufficiency with 25OHD3 levels <30ng/mL,
thus nearly 92% was bellow 30ng/mL. The incidence and severity of chronic fatigue, sleep
problems, attention and cognitive deficits after TBI are strongly and intricately related
(Schnieders, Willemsen, & de Boer, 2012) and improvements in post-TBI sleep disturbances
showed significant decrease of other neuropsychological impairments related to TBI (Chauhan,
2014).
It is worth noticing the work of researchers from Emory University, in Atlanta, Georgia,
since they have made crucial contributions to the areas of stroke and TBI research over the last
two decades. They focused on targeting multiple processes of acute head trauma by combining
two neuroprotective agents with the idea that the combination would exert synergistic benefits.
This concept was accepted by a panel of the National Health Institute with the idea of boosting
favorable outcomes and functionality following brain injury. The preclinical results with
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1,25OH2D3 administrated concomitantly with progesterone yielded significant improvements in
TBI and stroke models (Atif et al., 2013). Unfortunately, this hormonal combination failed to
translate with the same success as the clinical trials advanced (Stein, 2015). The Emory
University laboratories have demonstrated that vitamin D attenuates the inflammatory response,
protects neuronal and glia cells against apoptosis, exerts antioxidant protection, protects against
excitotoxicity from glutamate, may impart a positive impact in certain functionality outcomes
after ischemic damage (Atif et al., 2013), strengthen the integrity of the BBB and reduces
damage by oxidative stress (Won et al., 2015).
Vitamin D neuroprotection.
Vitamin D deficiency has been implicated in defective actions of macrophages involving
the secretion of pro-inflammatory cytokines and phagocytic performance. The connecting
element between the innate immunity and stimulation of toll-like receptors is vitamin D.
Moromizato and colleagues (2013), hypothesized that the elevated likelihood for sepsis or septic
shock among critically ill patients is due to these the toll-like pathways interacting with vitamin
D. VDR expression is induced by peripheral and neuronal immune cells activation. After
multivariable adjustment and random selection validation sub-analysis, vitamin D levels
<15ng/mL prior to admission were associated to a 2.5-fold increment on the risk for sepsis or
septic shock (Moromizato et al., 2013).
Stressed brain cells increase VDR expression and 1,25OH2D3 activation in cultured
animal cells (Fu et al., 2013; Obradovic et al., 2009) and in the brain of deceased patients with a
stroke. Similar findings concerning brain cells under ischemic stress were described by Ridder
and colleagues (2009), showing VDRs translocation into the nucleus from vitamin D hormone
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stimulation followed the ischemic event (Ridder et al., 2009). Vitamin D significantly decreased
cell death from glutamate excitotoxicity (Kajta et al., 2009), from absence of oxygen-glucose
(ischemia/reperfusion model) (Atif et al., 2013), from oxidative stress (Hur et al., 2014) and due
to tumor necrosis factor apoptosis-inducing ligand (TRAIL) (Obradovic et al., 2009).
Preclinical experiments have shown that vitamin D neuroprotective gains may require
preloading or pretreatment preceding exposure to harmful incident (Kajta et al., 2009; Obradovic
et al., 2009), and may be dose- and time-dependent. For example neurons from different regions
of the brain require higher or lower doses than others for the same benefit or in cases of delayed
treatment, higher concentrations may be required to reach therapeutic benefits (Kajta et al.,
2009).
Recent experiments confirm that activated microglia intensified the expression of 1,25hydraxolase and VDR preceding depression of nitric oxide (NO) synthesis and a 90%
improvement on cell viability, implying suppression of activated microglia by the active form of
vitamin D (Hur et al., 2014). Activated microglia promotes neuroinflammation by stimulating
mitogen-activated protein kinase (MAPK) pathways. However, vitamin D is capable of negative
regulating the phosphorylation of p38 (Huang et al., 2015; Hur et al., 2014; Obradovic et al.,
2009), extracellular signal-regulated kinase (ERK) (Fu et al., 2013; Huang et al., 2015) and JunN-terminal (JNK) (Huang et al., 2015) MAPK pathways. Increase in NR3 subunit by vitamin D,
dampens phosphorylation of ERK pathway by mediation of a nuclear binding transcription factor
(cAMP/Ca2+ response element binding protein or CREB) (Fu et al., 2013). Vitamin D’s
obstruction of p38 and ERK expression significantly hinders inducible nitric oxide synthase
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(iNOS), reduces intracellular production of ROS (Huang et al., 2015) and buildup of NO (Huang
et al., 2015; Hur et al., 2014).
1,25OH2D3 also prompt a marked decline in synthesis and signaling involving proinflammatory mediators such as interleukin-6 (IL-6) (Atif et al., 2013; Huang et al., 2015),
macrophage-inflammatory protein-2 (MIP-2) (Huang et al., 2015), and nuclear factor kappa-B
(NFκB) concentrations (Atif et al., 2013; Won et al., 2015). The significant declines of IL-6 and
MIP-2 at protein and mRNA sites were largely mediated by the inhibitory effects on p38, ERK
and JNK (Huang et al., 2015).
Hypoxic and mitochondrial injury stimulates activation of NFκB pathway. The activated
NFκB translocates into the nucleus, where p65 subunits acts as a transcription factors by binding
to a gene that upregulates MMP-9 expression (Won et al., 2015) and IL-6 (Fernández-Gajardo et
al., 2014) promoting neuronal inflammation (Atif et al., 2013). In vitro experiments showed a
marked decline in concentrations and expression of NFκB after vitamin D was added to brain
cultured cells. Thus blocking phosphorylation of NFκB reduces inflammation and disruption of
the BBB (Atif et al., 2013; Won et al., 2015).
Atif and colleagues (2013) from Emory University, found outstanding efficacy of vitamin
D in elevating heme oxygenase-1 expression to attenuate oxidative damage after ischemia, as
demonstrated by a twofold increment (Atif et al., 2013). Mitigation of free radical damage
increasingly causing lipid peroxidation and degradation of DNA is ameliorated by vitamin D
(Charier et al., 2015; Won et al., 2015). Vitamin D cause only a minor reduction of
malondialdehyde (a biomarker present following membrane oxidative degradation)
concentrations, however it produced a substantial boost in superoxide dismutase. Superoxide
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dismutase is the potent antioxidant enzyme behind the protective catalysis of superoxide (Ekici,
Ozyurt & Erdogan, 2009).
A combined in vitro/in vivo study showed that calcitriol, when administered within 30
minutes following a hypoxic-ischemic event, offered significant reduction of brain injury. The in
vitro portion of the study showed that glutamate excitotoxicity damage is significantly weakened
by administration of calcitriol to cultured cortical neuron and glia cells. Pretreatment and higher
doses of calcitriol yielded superior protection. Interestingly, these positive benefits were not
observed in cerebellar cells (Kajta et al., 2009). Vitamin D can ameliorate cell damage from
glutamate toxicity by increasing NR3 expression, subsequently antagonizing proinflammatory
extracellular signal-regulated kinase (ERK) MAPK pathway thought the activation of a nuclear
transcription factor CREB. CREB expression has an anti-apoptotic effect, stimulates
neurogenesis and may be helpful in protecting against glutamate excitotoxicity (Fu et al., 2013).
Extracellular glutamate in excess results in hyper-stimulation of low voltage calcium
channel and generates calcium influx rising to toxic levels (Fu et al., 2013). Positive modulation
of low voltage calcium channel subunit A1C (LVCC-A1C) has been observed in cultured
neurons after suppression of VDR (Gezen-Ak, Dursun & Yilmazer, 2013). Downwards
regulation of the LVCC-subunits is unleashed by vitamin D or VDR and thought to block
calcium influx. Additionally, vitamin D enhanced expression of calcium binding proteins thus
limiting free ions inside the cell (Groves, McGrath & Burne, 2014).
After exposure of cortical neurons to amyloid β, VDR expression was totally invalidated.
Meanwhile, treatment with vitamin D protected cortical neurons against toxicity from amyloid β
proteins through suppression of LVCC-A1C while stimulating the expression of VDR. Amyloid
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β accumulation had an opposite effect by enhancing LVCC-A1C and suppressing VDR
expression. This is interesting, since amyloid β accumulation has been proposed as a potential
etiology for Alzheimer disease and other dementias (Gezen-Ak, Dursun & Yilmazer, 2013).
Knowing that there is an upsurge of both amyloid β and its precursor protein after head trauma
(Fernández-Gajardo et al., 2014), and that it can suppressed vitamin D activities during the
secondary injury phase opens the possibility for therapeutic interventions. Studies on Alzheimer
patients showed that vitamin D improves amyloid β elimination and phagocyte engulfment in the
brain (Gezen-Ak, Dursun & Yilmazer, 2013).
Vitamin D considerably reduced permeability of viable brain endothelial cells under low
oxygen conditions though dose-mediated protection on the integrity of proteins along the tight
junctions, the space between endothelial cells that supports BBB integrity. Interruption of the
BBB during hypoxia or ischemia is mostly driven by excessive generation of ROS and NO
damaging cellular structures. VDR expression directed the antioxidant effects of vitamin D in the
protection of the BBB permeability by hindering oxidative stress.
Thus 1,25OH2D3 and VDR mediate the protection of tight junctions of endothelial cells
in the BBB in several ways (Won et al., 2015) by negatively impacting the activity of matrix
metalloproteinases (MMP), a group of enzymes that together with nuclear factor kappa-B (NFκB), are known to disrupt cellular membrane permeability subsequential to ROS stimulation.
Matrix metalloproteinase-9 (MMP-9) is an enzyme that sponsors mending of cell membranes. To
achieve restoration the MMP-9 simultaneously disintegrates tight junction proteins to repair the
membranes, thus worsening dysfunction of the BBB (Mayer et al., 2013; Won et al., 2015). As
MMP-9 concentrations grow following brain injury, it paves the way for BBB disruption through
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protein degradation (Won et al., 2015). MMP-9 is a proinflammatory mediator capable of
activating neuroglia cells (Mayer et al., 2013). After a hypoxic event, vitamin D is able to
promote the BBB impermeability by reducing MMP-9 expression (Won et al., 2015).
The abovementioned, are extremely important for brain cell protection after acute trauma,
since disruption of the BBB precedes infiltration of peripheral and blood cells into the brain
compartment that can result in neuronal and glia apoptosis (Fernández-Gajardo et al., 2014).
Blood is so detrimental to the brain that hemorrhages are indicators for more advanced
neurological impairment and higher mortality risk. When lysed blood comes into contact with
neuronal cells it exacerbates the cellular stress from excess calcium. Recent laboratory data
showed that axonal fragmentation began 12 hours after exposure of neuronal cultures to lysed
blood and progressed until the entire axon was destroyed. Vitamin D application showed
significant protection against blood-induced axonal fragmentation, but it did not offer a
significant protection against substances emitted from blood clotting (Charier et al., 2015).
In vivo experiments indicated that 1,25OH2D3 administration after an ischemic incident
induces smaller infarction volume (Fu et al., 2013; Kajta et al., 2009) and increased cell survival
(Atif et al., 2013), however, pretreatment exerted better results (Kajta et al., 2009). Data from
studies on ischemic strokes are provided, since clinical data of TBI, vitamin D, and ischemic
injury was not available at the time of this review. These findings may explain the observations
from retrospective and prospective studies from China, France and the USA, in which an inverse
association between vitamin D and infarction size was reported. Low vitamin D prior to
admission showed larger infarct volume (Turetsky et al., 2015; Wang et al., 2014), increase
severity on admission (assessed with the National Institutes of Health Stroke Scale) (Daubail et
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al., 2013; Wang et al., 2014) and longer hospitalization length after an ischemic stroke (Wang et
al., 2014), also served as an independent predictor for the magnitude of the outcomes. Two of the
studies found that low 25OHD3 predicted worse functionality outcomes at hospital discharged
(Wang et al., 2014) and at 90-days (Turetsky et al., 2015) and survivors were correlated with
higher serum 25OHD3 (Wang et al., 2014). Turetsky and colleagues (2015) stated that for every
10ng/mL reduction in 25OHD3 levels, there was a twofold increase for inferior outcomes at 90
days post-ischemic brain attack, and proposed exploration of 25OHD3 as a biomarker to identify
patients with heighten vulnerability for worse prognosis (Turetsky et al., 2015). All of the
observational studies used difference vitamin D references for their analysis, as seen on table 3.
Table 3: Incidence of vitamin D deficiency as defined by the above referenced studies.

Stroke patients
Country of origin
Serum 25OHD3
Percentage of
participants

Daubail et al., 2013

Turetsky et al., 2015

Wang et al., 2014

France
<10ng/mL

China
<29.9ng/mL

USA
<20ng/mL 25OHD3

33%

64%

68%

Significance of Vitamin D on Brain Health
The neurological implications of vitamin D levels and the mechanisms involved with
brain functions are still being assessed. Compelling evidence indicates that 1,25OH2D3 may
prevent brain cell damage by interacting with about 170 genes following ischemic injury and 32
transcription factors with gene upregulation potential (Ridder et al., 2009). An in vitro study
using cultured neuronal stem cells from human origin, found more than 180 proteins involved in
neurological processes and neurogenesis were expressed after the cells came into contact with
1,25OH2D3 (Obradovic et al., 2009).
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Noteworthy attenuation of the expression of iNOS, IL-6 and MIP-2 has been observed
with calcitriol (Huang et al., 2015). Genomic regulations of ion voltage channels on cell
membranes have been reported to aid in maintain ionic balance (Gezen-Ak, Dursun & Yilmazer,
2013; Groves et al., 2014). Thus, deficiency or insufficiency of vitamin D may enhance
vulnerability when facing the pathological alterations of TBI.
In summary, available biological data supports that 1,25OH2D3 and VDR expression
have regulatory influences in known secondary responses that follow a TBI. Given the results,
vitamin D promises to be a therapeutic agent to prevent the activation or slow down the
progression of the TBI-related inflammatory responses and BBB disruption. The emerging
literature associating vitamin D status with the prevention, prognosis, and progression of a large
number of neurological deficits and long-term neurodegeneration supports the need to expand
research.

Vitamin D Status Among the Military Population
New discoveries concerning vitamin D actions in multiple biological processes, as well
as neuroprotective features, could be relevant to military personnel recovering from TBI (Cui et
al., 2015; Wentz, Eldred, Henry, & Berry-Caban, 2014). Although only a few studies have
evaluated vitamin D levels among active military and veterans, the available evidence suggests a
high prevalence of deficiency and insufficiency (Alazzeh et al., 2015; Andersen et al., 2010;
Bailey, Manning & Peiris, 2012; Hiserote et al., 2016; Wentz et al., 2014).
A retrospective study of active duty (1,928) and veteran (1,125) military personnel,
examining medical records for 3,053 samples at the Womack Army Medical Center, Fort Bragg,
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North Carolina, showed that 57.3% of participants had either vitamin D deficiency or
insufficiency, regardless of the 35.1°N latitude of the sample. The findings (reference table 4 and
5 below) showed that 20.4% of the participants were deficient, 36.9% tested at insufficient levels
and 42.7% were between 30-100ng/mL (Hiserote et al., 2016).
Table 4: Service members by 25OHD3 level (Hiserote et al., 2016).

All service members
Mean 25OHD3

Deficiency
<20ng/mL
n= 623
14.65 + 3.44

Insufficiency
21-29ng/mL
n= 1,127
24.77 + 2.82

Sufficiency
30-100ng/mL
n= 1,302
38.94 + 9.83

Table 5: Vitamin D levels according to military status (Hiserote et al., 2016).

Mean 25OHD3

Active duty (n= 1,350)
27.79 + 11.28

Veterans (n= 1703)
30.47 + 12.55

To this date, perhaps the most significant study evaluating vitamin D levels among
military patients is the retrospective analysis of 15,340 individuals from six different facilities in
the southeastern United States. Although the sample was primarily comprised of white males
with an average age of 66.5 years, vitamin D deficiency (<20 ng/mL) was significant in all six
sites, even after correcting for seasonal and latitudinal variances. In fact, the highest vitamin D
levels were below 35 ng/mL at all locations, except for one site (Huntington) where it was
between 38-39 ng/mL. Moreover, deficiency was independently related to higher cost of health
care across the entire sample (as seen on figure 11). Health care cost was at least 70% higher for
patients who were deficient and did not receive a vitamin D follow up test in comparison to who
were either deficient or received a vitamin D follow up test. The deficient patients without a
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follow up test had nearly 300% higher health care cost than the non-deficient who received
follow up testing (Bailey, Manning & Peiris, 2012).

Figure 11: Total inpatient costs by VA site and vitamin D deficiency status
(Bailey, Manning & Peiris, 2012, p. 74).

A retrospective study analyzed of 3,608 American female veterans tested during a period
of ten years (2001-2010), found a 44% deficiency of 25OHD3 (<20 ng/mL) with a higher
incidence among minority veterans (Alazzeh et al., 2014). Another retrospective analysis of
vitamin D status among critically ill veterans between 1999 and 2009, found that 38% tested
deficient at <20ng/mL and 60% tested within the range for insufficiency (<30ng/mL) (McKinney
et al., 2011).
A pilot study examined the impact of 8 weeks of basic combat training (BCT) on the
vitamin D levels on new female recruits at the US Army BCT at For Jackson, South Carolina.
The data from the randomized control trial was collected during summer/fall training and used to
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evaluate vitamin D serum concentrations of the 74 trainees. The comparison of 25OHD3 levels
from baseline and the end of the 8 weeks of basic combat training showed the mean levels
declined from 72.9 +30.0nmol/L to 63.3 +19.8nmol/L, with lowest levels among non-Hispanic
black. This study documented a decline in 25OHD3 levels among young female recruits during
the summer-fall training, regardless of the time spent outdoors (Andersen et al., 2010).
The IOM and TES concluded that screening of vitamin D status for healthy,
asymptomatic individuals is not necessary, unless there are identifiable risks suggesting
otherwise (Holick et al., 2011; IOM, 2011b). Giving the significance of the evidence showing
high health care cost with low vitamin D levels and progressive decreased during outdoor
military training, it is appropriate to recommend evaluation of vitamin D optimization for active
duty members and veterans.
Vitamin D: Advancing Future Research.
In their review of literature, Wentz and associates (2014) suggest that achieving optimal
levels of vitamin D prior to injury may protect and improve rehabilitation efforts of wounded
soldiers, while improving their outcomes (Wentz et al., 2014). There may also be the potential
added benefits of improving survival rates for soldiers in critical condition, reducing disease
progression and decreasing clinical symptoms (Alazzeh et al., 2015; Cui et al., 2014; Eyles,
Burne & McGrath, 2013; McKinney et al., 2011; Moromizato et al., 2013; Toffanello et al.,
2014; Wentz et al., 2014).
Advantages of working with military subjects include easy access to conduct health
exams and laboratories prior to head trauma exposure. Monitoring and supplementation
interventions can be performed within cohorts with shared characteristics. Additionally,
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designing studies with subjects under a two or three year contract or with lifelong military
careers may improve attrition rates.
In order to advance vitamin D research and practices it is necessary to address the lack of
international reference values for screening, the need to standardize the assay methods, and
reanalyzed the epidemiological and clinical findings.
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CHAPTER 5: DISCUSSION
Active duty military and veterans share a history of exposure to TBI. TBI is responsible
for inflammatory and metabolic processes with long-term progression. Screening of vitamin D
status is a reasonable first step, given that adequate vitamin D levels prior to brain injury have
been shown to exert neuroprotective actions and slow the pathological changes after head
trauma.
The complexity of TBI management comes with acute and chronic pathologies. Clinical
presentation is as individualized and unique as the injury itself. The progression, outcomes and
response to current intervention protocols have made TBI a difficult disorder to treat.
To date, most research of TBI and vitamin D has been done in animal models. Thus far,
translating these models into clinical trials has proven to be challenging. However, in order to
improve knowledge, successes and failures are inherent, and arguably necessary in research.
The idea of having standard, acceptable measures to better guide future study of TBI has
been a long standing goal of the scientific and clinical communities. The shortcomings of the
methods used to measure outcomes contribute to the large number of clinical trial failures and
continue to hold back prospects of fulfilling this goal.
Neuroinflammatory pathophysiological alterations of ischemic stroke parallel those of
TBI. In reviewing human trials and observational studies of patients with hypoxic/reperfusion
injuries, it was evident that vitamin D exerts a neuroprotective action. It reduces the volume of
the injury, improves symptoms and prognosis, decreases mortality, lowers disability and is
associated with better functionality. There is still much to answer about possible physiological
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impact of low and insufficient vitamin D concentrations on health and thus far, causality is not
even part of the conversation.
However, it is hard to ignore the inconsistencies in vitamin D classification and reference
range used by many of the studies. Variations in optimization practice guidelines add to the
challenges surrounding a complex field and compound to the difficulties of designing
interventional trials. Consistency and validity of measuring methods are at the foundation of high
quality research and should be prioritized. Only time will tell if the scientific and medical
communities can indeed achieve consensus and provide the prevention and interventions of
vitamin D. Collaboration to develop a common set of guidelines will be needed, if health care
providers are to address clinical and subclinical deficiencies among military service personnel
utilizing evidence-based practices.
The number of combat injured service personnel surviving serious injuries will continue
to rise. Better, consistent diagnostics and treatments should be a priority for the nation. Accurate
diagnosis and high quality TBI clinical management have the potential to improve the lives of
veterans and improve their reintegration as civilians.
The scarcity of human studies on the neuroprotective effects of vitamin D on TBI-related
outcomes, confirms that there is a need in this area. Future research of TBI management could
include exploring the relationship of vitamin D screenings before combat exposure and post-TBI
outcomes. It could also incorporate prognosis predictions based on 25OHD3 levels and
investigating the possibility of long-term supplementation for the prevention and treatment of
chronic neurodegeneration after combat-related head trauma.
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CHAPTER 6: CONCLUSION
This review found compelling evidence supporting that the acute and chronic
pathological changes following TBI are closely associated with the neuroprotective mechanisms
of vitamin D. Calcitriol administration is considered safe, relatively low cost and screening risks
are fairly low. The question of the potential benefit of a supplementation program for military
personnel merits further inquiry. Furthermore, the evidence supports that an optimization
program for active duty and veterans promises to lower cost of health care. Thus, the potential
argument concerning the cost of vitamin D screening pales against the return on investment and
the human capital gains.
Studies evaluating vitamin D status among military personnel shows that deficiency and
insufficiency are prevalent, regardless of age, gender, ethnic background, or military status.
Ongoing warfare will continue to expose military service personnel to the risk of TBI. Sufficient
preclinical studies have shown that vitamin D neuroprotection is enhanced by preloading the
cells before exposure to trauma and in some instances neuroprotection can only be achieved by
meeting a specific range. Mounting evidence from clinical and epidemiological studies confirm
that low vitamin D levels predispose patients to poorer health consequences.
Soldiers, veterans and their families eagerly await evidence-based clinical practices that
can reduce disease burden by improving outcomes, recovery and minimizing long-term sequelae.
Based on the evidence reviewed, the medical community can no longer afford to ignore vitamin
D.
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APPENDIX A:
METHODOLOGY
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Appendix A: Methodology
Searched subject headings, subjects and abstracts for:
(“inflammatory cytokines” OR “neuroinflammat*” OR “immune regulat*” OR “inflammatory mediator” OR
“immune system” OR “MAPK” OR “neuron* disruption” OR “blood-brain barrier” OR “BBB” OR ”BBB
leakage” OR “brain-blood” OR ”membrane leakage” OR “L-type calcium channels” OR “calcium channel” OR
“ca* influx” OR “brain intracellular calcium” OR “reactive oxygen species” OR “ROS” OR “oxidative stress” OR
“oxidative damage” OR “ion gradients” OR “neurotoxicity” OR “excitotoxic*” OR “excitotoxicity” OR “cerebral
edema” OR “neuroedema” OR “apoptosis” OR “neurotrophic” OR “neurotrophic factor” OR “nerve growth
factor” OR “NGF” OR “proliferation,” OR ” lipid peroxidation” OR “hypoxi*” OR “cerebral ischemia” OR
“VDR*” OR “vitamin d receptor” OR “1α-hydroxylase” OR “VDR binding” OR “antioxidant” OR
“neuroprotect*” OR “regulat*” OR “modulat*” OR “Neuroprotective Agent” OR “cytotoxic*” OR
“pathogenesis”)

("vitamin D*" OR "vitamin-D*" OR
"Cholecalciferol" OR "calciferol" OR
"calcitriol" OR "*dihydroxyvitamin D"
OR "soltriol" OR "25OHD*" OR
"25(OH)D*" OR "1,25(OH)2D*")

AND

(“brain” OR “cerebral” OR “axonal” OR "brain injur*" OR
"brain trauma" OR "brain dysregulate*" OR "brain dysfunct*"
OR "traumatic brain injury" OR "brain concussion" OR "head
trauma" OR "concussion" OR "blast-related traumatic brain*"
OR "post-concussive" OR "post-traumatic brain" OR
"neuroinflammat*" OR “secondary damage” OR “primary
damage” OR “secondary injury” OR “primary injury”)

n = 773

EXCLUSION CRITERIA TERMS
(("sclerosis" OR "sclerotic" OR "autoimmune*" OR "Hyperammonemia" OR "spinal cord" OR "spine" OR
"tumor" OR "cancer" OR "carcinoma" OR "ethanol" OR "cardio*" OR "coronary" OR "renin-angiotensin" OR
"osteoporosis" OR "bone loss" OR "bone resorption" OR "respirat*" OR "lung" OR "muscle" OR "skin" OR
"liver" OR "kidney" OR "renal" OR "bowel diseases" OR "malabsorption syndrome" OR “digestive” OR
"thiamine" OR “folate” OR “B12” OR “B6” OR "vitamin A" OR “zinc” OR "diabetic" OR "insulin" OR
"hemodialysis" OR "parathyroid" OR "thyroid" OR "dehydroepiandrosterone" OR "vestibul*" OR “hearing” OR
"visual" OR “retina” OR "sepsis" OR "sperm" OR "dopamine" OR "ovarian" OR “pregnancy” OR “aging” OR
“65 years” OR "neonatal" OR "newborn" OR "infant" OR “children” OR “Cerebral Cavernous” OR “depress*”
OR “epilepsy” OR “shaken baby” OR “antipsychotic” OR “sleep disorder”) OR ("Parkinson" OR "autism" OR
“Alzheimer”)

n = 53

Further exclusion parameters: (1) studies related to science or medical specialties other than
neurology; (2) sample size of 1 patient; (3) age group: neonates, child* or infant or embryonic or
pediatric or adolesce* or 0-18 years or birth or pregnancy or aged or aging or elderly or over 65;
(4) did not include at least one of the topics from the inclusion criteria.
Articles were hand reviewed for inclusive criteria:
1) vitamin D neuroprotection and, 2) physiological alterations related to inflammation, interruption
of BBB, oxidative stress, and calcium concentration disruption.

n = 14
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INFLAMMATORY MEDIATORS
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Appendix B: Inflammatory Mediators
Pro-inflammatory
mediators

Action

Vitamin D

Mitogen-activated • Initiate neuroinflammatory
response by increasing synthesis
protein kinase
of pro-inflammatory mediators
(MAPK) are
(ROS, IL-6 and MIP-2) and NO
initiated via
accumulation (Huang et al.,
expression of the
2015).
NMDA receptor:
• ERK: signaling cascade to
1. p38
initiate apoptosis (Fu et al.,
2. extracellular
2013).
signal-regulated
kinase (ERK)
3. Jun-N-terminal
(JNK)

Reactive oxygen
species (ROS)
synthesis

•

•

•

•

• Suppresses phosphorylation of p38,
ERK and JNK MAPK pathways,
reduces NO accumulation and ROS
production and significantly
decreases IL-6 and MIP-2 (Huang
et al., 2015).
• Restore concentration of the NR3A
subunit by lessening its
degradation, consequently
triggering expression of the
calcium-response element binding
protein (p-CREB) (Fu et al., 2013).
• Hinder the phosphorylation
sequence of p38 MAPK and
consequently inhibits expression of
inducible nitric oxide synthase
(iNOS), accumulation of nitric
oxide (NO) and synthesis reactive
oxygen species (ROS) (Hur et al.,
2014).
Lipid peroxidation (Ekici et al., • Reduces intracellular production of
2008), degradation of DNA
ROS by obstructing p38 and ERK
(Fernández-Gajardo et al., 2014)
expression in cultured brain cells
and initiates endothelial and
(Huang et al., 2015).
neuronal apoptosis (Won et al.,
• Significant improves cell viability
2015).
following exposure to ROS (Won
Activates NJK MAPK, triggers
et al., 2015).
cellular edema, calcium influx
• Mitigates free radical damage
and metabolic collapse
increasingly causing lipid
(Fernández-Gajardo et al., 2014).
peroxidation and ameliorates
Decrease neurotrophic factors,
degradation of DNA (Charier et al.,
worsen cognitive decline and
2015; Won et al., 2015).
neuronal communication, and
• Vitamin D significantly inhibited
increase BBB permeability
mitochondrial ROS production
(Fernández-Gajardo et al., 2014).
through VDR expression
endothelial cells (Won et al., 2015).
Promotes expression of NFκB
and MMP-9 (Won et al., 2015).
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Pro-inflammatory
mediators
Nitric oxide (NO)
accumulation

Action
• Suppresses enzymatic activity in
the mitochondria thus reducing
adenosine triphosphate (ATP)
production (Fernández-Gajardo
et al., 2014; Huang et al., 2015;
Hur et al., 2014).
• Foster ROS synthesis (Huang et
al., 2015).

•
Inducible nitric
oxide synthase
(iNOS)
•
Matrix
metalloproteinase9 (MMP-9)
•
upregulation

•

Nuclear factor
kappa-B (NFκB)

Vitamin D

•

•

Toll-like receptors •
(TLR)

• Obstruction of p38 and ERK
expression significantly decreases
buildup of NO (Huang et al., 2015;
Hur et al., 2014).
• Expression of 1,25-hydraxolase
and VDR preceded decline of nitric
oxide (NO) synthesis and a 90%
improvement on cell viability (Hur
et a., 2014).
Linked to cognitive deficits in
• Significantly hinders iNOS
older adults (Huang et al., 2015).
expression by limiting activation of
p38 and ERK (Huang et al., 2015).
MMP-9 is capable of activating • Protects BBB integrity after a
neuroglia cells (Mayer et al.,
hypoxic event, by reduced
2013).
expression of transcriptor factor
Sponsors mending of cell
that promotes MMP-9 (Won et al.,
membranes, but at the same time
2015).
it disintegrate proteins of the
BBB tight junctions (Mayer et
al., 2013; Won et al., 2015).
As concentration rises after
injury, it produces protein
degradation that leads to
interruptions of BBB (Won et
al., 2015).
• Marked decline in concentrations
Activation of NFκB pathway
allows it to translocate into the
of NFκB (Atif et al., 2013), blocks
nucleus, where p65 subunit acts
phosphorylation and prevents
as a transcription factor by
translocation and gene expression.
binding to a gene that
Thus, protects BBB integrity by
upregulates MMP-9 production
reduction on MMP-9
(Won et al., 2015).
concentrations (Won et al., 2015).
NFκB binding to genes increases
IL-6 (Fernández-Gajardo et al.,
2014) promoting neuronal
inflammation (Atif et al., 2013).
Proteins capable of recognizing • Vitamin D is the mediator between
indicators of tissue damage and
TLR and activation of innate
aid in communication of
immunity. Low levels had a 2.570

Pro-inflammatory
mediators

Glutamate
excitotoxicity

Action

•

•

Low voltage
calcium channel
(LVCC) subunit
A1C

•

•

•

•
•

amyloid β
excitotoxicity

•

Vitamin D

neuroglia by releasing
fold increment on the risk for
chemokines (Mayer et al., 2013),
sepsis or septic shock in vulnerable
and may be involved in an
patients. (Moromizato et al.,
elevated likelihood for sepsis or
2013).
septic shock among critically ill • Vitamin D can down regulate the
patients (Moromizato et al.,
expression of TLR-8 and its direct
2013).
gene transcription (Huang et al.,
2015).
Overstimulates low voltage
• Calcitriol significantly lessened
calcium channel (LVCC) and
damage by glutamate in cultured
leads to deregulation of
cortical neuron and glia cells.
intracellular calcium by
Pretreatment and higher doses of
promoting massive influx, thus
calcitriol yielded better protection
worsening of calcium influx and
(Kajta et al., 2009).
cellular edema (Fernández• Ameliorate cell damage by
Gajardo et al., 2014).
increasing NR3 expression,
Causes necrosis and apoptosis of
subsequently antagonizing
neuronal cells (Charier et al.,
proinflammatory ERK MAPK
2015).
pathway (Fu et al., 2013).
Up-regulation suppresses
• Positive modulation of low voltage
expression of vitamin D
calcium channel subunit A1C
Receptor (VDR) by promoting
(LVCC-A1C) has been observed in
amyloid- β accumulation.
cultured neurons after suppression
Calcium is cytotoxic at high
of VDR (Gezen-Ak, Dursun &
levels (Gezen-Ak, Dursun &
Yilmazer, 2013). Downwards
Yilmazer, 2013).
regulation of the LVCC-subunits is
Disrupts permeability of
unleashed by vitamin D or VDR
mitochondrial membrane, which
and thought to block calcium
compromises membrane action
influx.
potential and uncouples ATP
• Additionally, vitamin D enhanced
production.
expression of calcium binding
Worsens oxidative stress
proteins thus limiting free ions
(Fernández-Gajardo et al., 2014).
inside the cell (Groves, McGrath &
Low ATP production will lead to
Burne, 2014).
dysregulation of membrane
transport proteins (Shi et al.,
2015).
Suppresses activation of vitamin • Protected cortical neurons against
D receptor while promoting the
toxicity from amyloid β proteins
expression of LVCC-A1C.
through suppression of LVCC71

Pro-inflammatory
mediators

Action

Vitamin D

• Accumulation is strongly
associated to the onset of
Alzheimer disease (Gezen-Ak,
Dursun & Yilmazer, 2013).

•

A1C while stimulating the
expression of VDR.
Improves amyloid β elimination
from the brain (Gezen-Ak, Dursun
& Yilmazer, 2013).
Marked decline was mediated by
inhibited expression of protein and
gene transcription, and by blocking
the phosphorylation of MAPK
pathways (Huang et al., 2015).
Marked decline in synthesis and
signaling at protein and mRNA
sites (Atif et al., 2013), were
largely mediated by vitamin D
inhibitory effects on p38, ERK and
JNK (Huang et al., 2015).
In animal experiments, deficiency
was linked to elevated cytokines in
the brain without a trauma,
including IL-6 (Groves, McGrath
& Burne, 2014).
Vitamin D application protected
brain cells against blood-induced
toxicity and this effect was
enhanced by concomitant use of an
N-methyl D-aspartate (NMDA)
glutamate receptor antagonist
(Charier et al., 2015).
Inhibits signaling activity (Kajta et
al., 2009).

Macrophageinflammatory
protein-2 (MIP-2)
release

• A chemokine that promotes
inflammation (Huang et al.,
2015).

Interleukin-6
(IL-6)

• Is a cytokine required to activate •
astrocytes (Mayer et al., 2013).
• Following brain trauma, IL-6
appears to have positive effect
on neuronal survival (Mayer et
al., 2013), such as improving
survival and differentiation of
•
oligodendrocytes (Shi et al.,
2015).

Blood toxicity

• Blood-driven axonal
•
fragmentation was noted to
begin 12 hours after exposure
and progressed to axonal death
(Charier et al., 2015).
• Initiates inflammation and
toxicity (Chauhan, 2014).
• Activated by lysed mitochondria, •
this messenger is capable of
triggering apoptosis (Atif et al.,
2013).
• After infiltration, these cells
• VDR expression and 1,25OH2D3
assist neuroglia cells in the brain
activation are induced by
by promoting inflammation and
peripheral and neuronal immune
produce toxic concentrations of
cells activation, which in turn
nitic oxide (Fernández- Gajardo
controls feedback mechanisms that
et al., 2014).
diminish possible damage from
overactive immune reactions
• Promotes oxidative stress by

Caspase-3

Peripheral
Leukocytes

72

•

Pro-inflammatory
mediators

Anti-inflammatory
mediator

Action

Vitamin D

increasing production of nitric
oxide (NO) (Fernández-Gajardo
et al., 2014).
• Prompts additional recruitment
of glia and peripheral immune
cells resulting in a systemic
immune reaction (Mayer, Huber
& Peskind, 2013).

(Groves, McGrath & Burne, 2014;
Moromizato et al., 2013).
• Deficiency is connected to
defective actions of macrophages
involving secretion of proinflammatory cytokines and
phagocytic performance
(Moromizato et al., 2013).

Neuroprotective actions

Vitamin D

• Antagonizes extracellular signalNR3A NMDA
regulated kinase (ERK) MAPK
glutamate receptor
pathway by phosphorylation
subunit
CREB, a protective nuclear
(found in brains of
signaling protein.
mammals)
• Reduces cell membrane
permeability to calcium.
• Co-expressed with NR3B,
decreases calcium influx into
mitochondria (Fu et al., 2013).
2+
cAMP/Ca -respon • Stimulates neurogenesis, and
may be effective in protection
se element binding
cells from glutamate
protein (CREB), a
excitotoxicity (Fu et al., 2013).
nuclear
transcriptor factor
• Potent antioxidant enzyme
Superoxide
behind the protective catalysis of
dismutase
superoxide (Ekici, Ozyurt &
Erdogan, 2009).
• Produces potent antioxidant
heme
molecules in neuronal and
oxygenase-1
neuroglia cells (Atif et al.,
expression
2013).
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• Increases NR3A concentration by
decreasing its degradation,
consequently triggering expression
of the calcium-response element
binding protein (p-CREB), an antiapoptotic mechanism (Fu et al.,
2013).

• Increases expression, thus
promoting cell viability (Fu et al.,
2013).

• Produced a substantial boost in
superoxide dismutase (Ekici,
Ozyurt & Erdogan, 2009).
• Vitamin D produced a twofold
increment, thus attenuating
oxidative damage after ischemic
event (Atif et al., 2013)
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